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The study of glycosylation is an emerging field that aims to understand the structure, synthesis and 
function of the commonly found molecules known as glycans. This integrative area of study covers 
many sub-domains such as chemistry, biology and informatics. 
 
Structurally, glycans are aggregate molecules, composed of a set of monosaccharides linked together 
through glycosidic linkages to form oligo or polysaccharides. Glycans are commonly found conjugated 
to other molecules such as proteins and lipids, or as free molecules in their own right. 
 
The biosynthesis of glycans is not template-based — a simple reading of the genome or the proteome 
will not yield any information as to the total set of glycans in a system (also known as the glycome). In 
fact, the biosynthesis of glycans follows a complex pathway that depends on many factors, resulting in 
unique glycosylation profiles for sub-systems and tissues. 
 
In order to overcome the inability to predict the complete glycome, efforts have been made to develop 
glycan databases that collect the observed glycans for a diverse set of systems. These databases are 
critically important to the development of the field, as they represent the knowledge base; the ability to 
query and search this information is an integral part of the toolset that researchers use to make further 
discoveries. 
 
The open model for database curation is attractive for the low-maintenance, decentralised nature of 
data collection. However, the use of open curation has implications for the quality of the data, which 
must be maintained through the implementation of validation procedures. This thesis is an investigation 
into the use of automatic validation techniques within openly curated databases. 
 
One possible application for this technology is within the EUROCarbDB project — a Europe wide 
effort to build an openly curated database that allows for easy deposition of glycan structures as well as 
the associated primary data used to establish each structure.  
 
The main aims of this thesis are to establish a method for automatically validating structures deposited 
into a glycomic database in order to maintain its quality; to ascertain whether it is possible to use these 
validation methodologies to obtain an estimate of the size of the human glycome; and to promote the 
distributed nature of the EUROCarbDB project, so as to provide a testing ground for the validation 
techniques. 
 
The main achievements in this thesis are many. First and foremost, I developed an algorithm for 
validating structures against pathway data. Also, I investigated the ability of the pathway and 
enzymatic data to explain the synthesis of human structures. Anomalous enzymatic data was identified 
for further examination, and the size of the human glycome was successfully estimated. Finally, a 
networking layer was established within the EUROCarbDB, necessitating the future use of the 
validation algorithms. 
Automatische Validierung von Glykanstrukturen in 
verteilten Datenbanken 
(Automatic validation of glycan sequences in distributed 
databases) 
Hiren Joshi 
 
Betreuer: Prof. Sabine Strahl 
 
Der Forschungsbereich Glykobiologie integriert wissenschaftliche Erkenntnisse aus der Chemie, 
Biologie und der Informatik mit dem Ziel, die Struktur, Synthese und die Funktionen von Glykanen zu 
untersuchen.  
 
Glykane bestehen aus Monosacchariden, welche mittels glykosidischen Verbindungen zu Oligo- oder 
Polysacchariden verkettet werden. Man findet sie meistens gebunden an Proteine oder Lipide oder als 
freie Moleküle. Die Struktur und Synthese der Gesamtheit aller Glykane (das Glykom) ist nicht direkt 
im Genom oder Proteom kodiert, sondern erfolgt durch eine Enzymkaskade und wird durch Faktoren 
wie Expressionsprofil der Enzyme und Verfügbarkeit von Monosaccharid-Substraten beeinflusst.  
 
Das Resultat ist ein heterogenes Glykosylierungsprofil in den verschiedenen Gewebetypen und 
anatomischen Strukturen. 
 
Datenbanken dienen der Archivierung von funktionellen und strukturellen Informationen über Glykane 
und ermöglichen deren Analyse mittels rechnerischen Ansätzen. Diese Datenbanken, besonders die 
Qualität der darin enthaltenen Daten, sind von zentraler Bedeutung für die Forschungsgemeinschaft. 
 
Für die Sammlung von dezentral produzierten Forschungsergebnissen in Datenbanken ist ein offenes 
Kurationsmodell attraktiv, da die Erzeuger der Daten diese selbständig in die Datenbasis einfügen. Um 
eine hohe Qualität und Konformität der Daten zu gewährleisten ist die Entwicklung automatisierter 
Methoden erforderlich.  
 
Die Zielsetzung dieser Arbeit ist die Entwicklung von Methoden zur Qualitätskontrolle in Datenbanken 
mittels automatischen Ansätzen zur Validierung von Glykanstrukturen. Eine Anwendung der 
entwickelten Verfahren zur Herleitung der Größe des menschlichen Glykoms und Integration der 
entwickelten Technologien findet sich im Rahmen des EUROCarbDB Projektes. Dieses Projekt befasst 
sich mit der Etablierung einer offen kuratierten Datenbank zur Archivierung von Glykanstrukturen und 
assoziierten strukturaufklärenden Messdaten. 
 
Die Ergebnisse umfassen die Entwicklung eines Algorithmus zur Validierung von Glykanstrukturen 
mittels Informationen über deren Biosynthese. Nicht verifizierbare Enzymdaten und Glykanstrukturen 
wurden identifiziert und eine Größenbestimmung des humanen Glykoms durchgeführt. Des Weiteren 
wurde EUROCarbDB mit Netzwerk-Funktionalität ausgestattet, welche die in dieser Arbeit 
entwickelten Methoden anwendet. 
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Preface
T
HE STUDY OF GLYCOSYLATION is an emerging field that aims to understand the structure,
synthesis and function of the commonly found molecules known as glycans. This integra-
tive area of study covers many sub-domains such as chemistry, biology and informatics.
Structurally, glycans are aggregate molecules, composed of a set of monosaccharides linked
together through glycosidic linkages to form oligo or polysaccharides. Glycans are commonly
found conjugated to other molecules such as proteins and lipids, or as free molecules in their own
right.
The biosynthesis of glycans is not template-based — a simple reading of the genome or the
proteome will not yield any information as to the total set of glycans in a system (also known as
the glycome). In fact, the biosynthesis of glycans follows a complex pathway that depends on
many factors, resulting in unique glycosylation profiles for sub-systems and tissues.
In order to overcome the inability to predict the complete glycome, efforts have been made
to develop glycan databases that collect the observed glycans for a diverse set of systems. These
databases are critically important to the development of the field, as they represent the knowl-
edge base; the ability to query and search this information is an integral part of the toolset that
researchers use to make further discoveries.
The open model for database curation is attractive for the low-maintenance, decentralised na-
ture of data collection. However, the use of open curation has implications for the quality of
the data, which must be maintained through the implementation of validation procedures. This
thesis is an investigation into the use of automatic validation techniques within openly curated
databases.
One possible application for this technology is within the EUROCarbDB project — a Europe
wide effort to build an openly curated database that allows for easy deposition of glycan structures
as well as the associated primary data used to establish each structure.
The main aims of this thesis are to establish a method for automatically validating structures
deposited into a glycomic database in order to maintain its quality; to ascertain whether it is
possible to use these validation methodologies to obtain an estimate of the size of the human
glycome; and to promote the distributed nature of the EUROCarbDB project, so as to provide a
testing ground for the validation techniques.
The main achievements in this thesis are many. First and foremost, I developed an algorithm
xvii
for validating structures against pathway data. Also, I investigated the ability of the pathway
and enzymatic data to explain the synthesis of human structures. Anomalous enzymatic data was
identified for further examination, and the size of the human glycome was successfully estimated.
Finally, a networking layer was established within the EUROCarbDB, necessitating the future use
of the validation algorithms.
xviii
Chapter 1
≈
Glycobiology and
glycobioinformatics
G
LYCOSYLATION IS THE MOST COMMONLY OBSERVED — and most inherently diverse —
post translational modification in biological systems, and is also the most inherently di-
verse. The regulation, function and structure of the glycans that result from glycosyla-
tion are the subject of the field of glycobiology. Glycans are synthesised as a product of genes and
proteins. It is through proteins — specifically the glycan-related enzymes — that glycan synthesis
is primarily effected. Regulation of synthesis occurs in a non-template, systems-based manner
[1], involving many factors ranging from gene expression to substrate availability. Coupled with
the branching nature of glycans, this results in the diversity of glycan products. The study of
glycosylation is a difficult area due to the complexity of the structures being examined.
1.1 Glycobiology
1.1.1 History
The study of glycobiology has historically been approached from two sides-the study of carbo-
hydrate chemistry, and the study of biochemistry. An early pioneer in the field of carbohydrate
chemistry was Emil Fisher, who studied simple carbohydrates as early as 1891. The field of glyoco-
biology grew during the 20th century (reviewed in Roseman [2]) with improvements in analytical
techniques. The term glycobiology was coined in 1988 by Rademacher, Parekh and Dwek [3].
1.1.2 Structure
The term glycan can often be used interchangeably with carbohydrate. Monosaccharides, disac-
charides, oligosaccharides and polysaccharide are all carbohydrates. Both oligosaccharide and
polysaccharide have well defined meanings with respect to the structure of sugars. Polysaccha-
rides are large polymers, while oligosaccharides are smaller glycans. Monosaccharides are gen-
erally found as cyclic structures, with 3 to 10 carbon atoms within the ring. See Figure 1.1 for
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examples of some common monosaccharides.
O
OH
OH
OH
HO
HO
Gal Glc Fuc
Man
O
OH
OH
OH
HO
HO
O
OH
HO
OH
HO
CH3
O
OH
NHAc
OH
HO
HO
GalNAc GlcNAc
O
OH
HOOH
HO
HO
O
OH
NHAc
OH
HO
HO
Figure 1.1: Hayworth projections of some common human monosaccharides.
Glycans are found either conjugated to other molecules, or as free molecules in their own
right. Glycans can be found attached to proteins and lipids, or can form parts of structures
such as the Glycosylphosphatidylinositol (GPI) anchors and Glycosaminoglycans (GAG)s. Gly-
cans are attached to proteins through an asparagine, serine or threonine amino acid. Lipids
are joined to the glycan through a ceramide unit. GPI anchors are attached via phosphatidyli-
nositol, whereas GAGs are N-linked (keratin sulfate) or O-linked (other GAGs) to proteins to
form molecules known as proteoglycans. The attachment point on the non-carbohydrate com-
ponent of the molecule can be used as a classifier for the glycans: N-linked, O-linked, GAG,
Glycosphingolipid (GSL) or GPI anchor. This classifier also gives hints as to the structural mo-
tifs found on the attached structures, since each point has different families of structures attached.
1.1.3 Function
Elucidation of the relationship between glycan structure and function is one of the main goals of
glycomic analysis. By clarifying the ways that structure affects cellular function, the medical ap-
plications of glycans can be revealed. Currently, relatively little is known about the exact function
of various structural features in glycans, and the mechanisms by which function is effected are
varied. Generally, the main mode of action is through protein-carbohydrate interaction — specifi-
cally through the interaction with lectins, a family of carbohydrate-active proteins known to bind
glycan epitopes.
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Recognition Glycan recognition is the most general mechanism of inferring a function for a
glycan. Lectins contain carbohydrate-recognition domains which serve as selectors of particu-
lar glycan epitopes or structural features. By either having non-binding functional domains, or
forming complexes with other functional molecules, different behaviour can be associated with
recognition of the glycan sequence. Receptor epitopes can range from being very specific — on
the level of ring substitution positions (such as haemagglutinin binding specifically to NeuAc
linked to a residue on a 6-substituted residue [4]) — to non-specific (such as binding to a single
monosaccharide regardless of the neighbouring residues). In a protein synthesis quality control
role, Endoplasmic Reticulum Associated Protein Degradation (ERAD) is controlled by mannose
trimming [5], requiring the protein conformation-dependent loss of mannose units to ensure that
the protein is degraded at the right point. Glycan tagging is a specific feature of the generalised
recognition mechanism which uses the properties of the conjugated molecule to conditionally
modify the appearance of glycan receptor epitopes.
Tagging Tagging of glycoconjugates occurs when the properties of the conjugated molecule di-
rect the addition of glycan tags onto the molecule. In the case of glycoproteins, the protein confor-
mation can be used to determine whether a particular glycan epitope is available for lectin bind-
ing. For example, an improperly folded glycoprotein in the calnexin-calreticulin cycle is recog-
nised by a glycosyltransferase, causing it to bind to calnexin or calreticulin [5]. The conformation
of the conjugated molecule triggers the addition of a monosaccharide residue, which causes the
glycoconjugate to be sorted by a glycan tag-specific lectin. Similarly, a GlcNAc-phosphate trans-
ferase is used to tag lysosomal hydrolyses for transport away from the Golgi. Following tagging,
a GlcNAc glycosidase is applied, leaving a mannose-6-phosphate epitope which is recognised by
a lectin that sorts the hydrolyses to the endosomes.
Protection Certain glycoproteins such as LAMP-1 and LAMP-2 are highly glycosylated, result-
ing in the formation of an almost contiguous carbohydrate coat that protects the proteins against
degradation by lysosomal proteases [5]. Glycans have even been found to play a role in anhydro-
biosis [6].
Promotion of folding Glycosylation promotes the folding of proteins such that more compact
conformations are achieved [5]. The role of glycans in the folding process has been documented
[5], with effects such as compact β turns being realised through the presence of a GlcNAc disac-
charide at asparagine glycosylation sites.
Other mechanisms Glycosylation is also known to be involved in cell-cell adhesion [7] and re-
ceptor activation (such as with EGFR and TGF-β receptor [8]).
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1.1.4 Disorders and disease
Genetic disorders of glycosylation have been extensively reviewed [9, 10, 11], and have been found
to result in a variety of phenotypical observations. Deficiencies in glycosylation enzymes cause
such phenotypes as muscle-eye brain disease, Fukuyama congenital muscular dystrophy, galac-
tosemia and inclusion cell disease (see Table 2 in [9]). Also, the various disorders classified under
the Congenital Disorder of Glycosylation (CDG) family are related to deficiencies in enzyme syn-
thesis.
The mechanisms behind these disorders involve the disruption of various pathways as a result
of the absence of a particular enzyme. By disrupting the synthesis of glycans, various structural
epitopes are not exhibited, which in turn affects processes such as protein folding and lectin bind-
ing.
O-linked glycans on mucins can act as pathogen decoys, mimicking lectin receptors in human
resistance to oral and mucosal infection [12]. As part of the human immune system, many lectins
bind specifically to bacterial glycans, resulting in the recognition of foreign pathogens.
1.1.5 Analysis
In general, the study of glycomics involves one or more of the many techniques that can be used
to glean insight into the structure, function and behaviour of glycans in a whole system [13].
Combinations of Mass Spectrometry (MS) [14] and High Performance Liquid Chromotography
(HPLC) [15] are used as the primary methods of sequence analysis within glycomics. These tech-
niques allow for qualification and quantification of glycan sequence with small amounts of sam-
ple. Two types of analysis can be performed— single structure sequencing (typically using multi-
ple stage fragmentation MS) and glycan profiling (giving an overview of the diversity of the gly-
can molecules found). Each of these analysis methods is somewhat limited in the amount of data
it can provide. The most information-rich analytical technique is Nuclear Magnetic Resonance
spectroscopy (NMR) spectroscopy [16], which results in fully characterised structures. NMR has
the drawback that large amounts of sample are required to obtain a structure.
The analysis of the data acquired throughMS and HPLC requires some sophisticated bioinfor-
matics to extract the relevant information. A number of algorithms [17, 18, 19, 20, 21] have been
developed to aid in the interpretation of data (reviewed in [22]); all of them require knowledge of
current structures and biosynthetic pathways.
Recently the use of various forms of glycan arrays as an analytical technique has been pur-
sued. The two forms of glycan-related arrays are gene micro-arrays [23, 24] and glycan arrays
[25]. Whereas glycan arrays allow for the parallel assessment of the lectins present, gene micro-
arrays allow for expression profiling of glyco-active enzymes.
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1.2 Glycobioinformatics
1.2.1 Databases
Glycobioinformatics is a nascent field with few dedicated practitioners, primarily due to the im-
maturity of the field as a whole. A number of groups work on the informatic analysis of glycans,
each taking a distinct approach (reviewed in [26, 27, 28]). The majority of efforts in the area of
glycobioinformatics have centred around the development of databases.
The development and maintenance of knowledge bases — encapsulating bodies of knowl-
edge for a domain — are key to the practice of scientific disciplines. In molecular biology, the
use of sequence databases is a standard procedure, as evidenced by genomic and proteomic disci-
plines using genome data and the Universal Protein resource (UniProt) resource [29] as reference
databases. The free availability of reference data has spurred development in this area, opening
up new avenues for research. In contrast to the genomic and proteomic databases, glycomics is
missing an appropriate database to act as a reference resource.
Since the late 1980s, there have been multiple efforts to collect information on glycans and
make it available through a reference database. For the majority of these efforts, database entries
have been sourced from previously published data. The curation of data from literature is an
expensive and time-consuming exercise, requiring at least two dedicated glycoscientist curators,
database Information Technology (IT) staff, and a senior glycoscientist to oversee management. In
addition, effectivemechanisms to keep track of new glycan publications, and access to the journals
themselves, are required.
Curation-based databases — KEGG [30], Glycosciences.de [31], BCSDB [32] and Glycominds
[33] — are based upon the early Complex Carbohydrate Research Center (CCRC) Complex Car-
bohydrate Structural Database (CCSD) [34] (also known as CarbBank). Each database has trans-
formed and cleaned the CarbBank data, and then made either all or a subset of the data available
via the internet. Each database project then supplemented their data with new entries from ad-
ditional sources. However, as each of the databases took a different approach to their design,
interoperability between them is non-existent.
In addition to information from published sources, a great deal of structural and ancillary data
is being generated in various glycomics labs. This data is stored in an ad-hoc format: hand-written
in labbooks, stored in a proprietary electronic format, or simply sketched on a piece of paper. The
lack of uniformmeta-data and annotation means that over time this data will be lost and any kind
of data mining cannot be performed. There is a clear need to provide methodologies for capturing
this meta-data, and then providing a pathway for its eventual publication and distribution.
Currently, no data repository exists that can enumerate all the structures found in any particu-
lar glycome. However, significant interest in the area of glycomics, coupled with the large amount
of data being collected in individual labs, means it is now feasible to create a comprehensive data
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set. Unfortunately, this data is not being captured in a uniform way, and will likely remain stored
using various proprietary schemas for the foreseeable future. By creating an end-user curated
database, it will be possible to create a long-lived database resource that maintains quality and
reliability.
1.2.2 The need for glycan databases
It is logical to ask what the uses of glycan databases are — especially for the scientists who are
being asked to fill these repositories with useful data. From a short-term perspective, there are
few real perceived benefits to the end user. A more complete database may help with the imple-
mentation of various analytical tools to facilitate the analysis of data, but progress in this area is
hampered more by the dearth of freely available algorithms. Glycan databases will probably pro-
vide the most utility in acting as a shortcut to finding reference information on various structures
of interest. In this way, the databases act as brokers of information to the users — filtering out
unnecessary data points so that the user can focus only on relevant data for further analysis. For
example, Hizukuri et al. have performed data mining on the Kyoto Encyclopaedia of Genes and
Glycans (KEGG) database [35] that has yielded glycan structures relevant to leukaemia [36].
This role as a filter carries through to the longer-term goals of these types of database. As
the data sets approach completeness, data mining becomes more feasible. It is at this point that
bioinformatics moves from its supporting role to helping to direct research. By mining the data
set, it is possible to find new avenues of research which would otherwise require an inspiration to
identify. Data mining essentially mimics what the human mind does when it recognises patterns
in data, but on a much larger scale. By performing transformations on the data, new correlations
can be identified, models tested and further experiments hypothesised.
1.2.3 Centralised curation
Databases have traditionally been maintained as centralised resources. This was often necessary
because the infrastructure surrounding the database was focused on a single point of data entry,
and the database servers themselves were expensive. In the last 15 years, the proliferation of
commodity software and the internet have mitigated much of the expense of hosting a database.
Although equipment costs are now limited, maintenance and curation costs remain high for
fully centralised databases. As the majority of data that was collected by centralised glycan
databases required the review of literature and manual curation – necessitating the involvement
of skilled professionals – the expense of such efforts often became prohibitive. Depending on the
curation procedure, data may need to be double-checked to ensure its quality, effectively doubling
the workload of entering a single entry.
A centrally curated database yields significant advantages in terms of the quality of the data,
as the entire process is controlled by a central group of curators, and inconsistencies can be tightly
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regulated. Naturally, the curation process is unable to fix problems in the data that stem from the
original publication. For example, much experimental meta-data remains unpublished due to the
lack of space in journals. Although the data may be of reporting quality in the literature, it may
not be detailed enough for bioinformatic analysis.
Although the results from centralised curation are good, the process is highly dependent on
funding; once the money runs out, the database tends to stagnate. This is particularly evident
with CarbBank and GlycoSuiteDB [37]. As the establishment of a glycome repository is a long-
term project, the longevity of any database must be ensured.
1.2.4 Open curation
In contrast to centrally curated databases, open databases allow the unrestricted entry of data
by interested parties. This requires no outlay for curation, but makes it difficult to maintain the
quality of data. As a result of their open nature, publicly curated databases need to have measures
in place to prevent bad data being inserted, either inadvertently or maliciously. These measures
should attempt to ensure both syntax and context validity of the data as it enters the database.
For open curation to be successful, data must be validated without the need for centralised
curation. This can be controlled either by end users, or through automatic validation procedures.
To perform end-user validation, people need to be encouraged to contribute corrections to data.
A study of the social methods to achieve this is beyond the scope of this thesis, but there are a
number of guiding principles to making end-user validation feasible.
Ownership Users are more likely to maintain the data in a publicly curated database if they feel
some ownership of its contents. Crediting data to its original source will give this person a vested
interest in correcting their data, since their name and reputation is at stake.
Linus’ Law Named after open-source programmer Linus Torvalds, this law states that “given
enough eyeballs, all bugs are shallow”. In this context, this means that with a sufficient level of
peer review of records, the number of errors found in the database will tend towards zero. In
addition to identifying the errors, it is also important that peer reviewers can modify the data
without onerous procedural overheads. This follows the Wiki model for peer review of data.
Tooling It is critically important that suitable tooling exists to facilitate the previous two points.
Appropriate tools and user interfaces remove the complexity of the data entry process, and present
a simple workflow to end users. Key to the success of these tools is the timeliness of validity check-
ing. Immediate feedback as to the context and syntax validity of entered data encourages the entry
of correct data. Similarly, the benefits for the end user need to be clear — it must be obvious what
the advantages of annotating data are in terms of scientific output or increased analytical capabil-
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ities.
Themost technologically expedient technique formost openly curated databases is to use these
manual checking methods to maintain validity. For larger databases (such as Wikipedia [38]),
many of these social and procedural methods can be used. However, for lower-traffic databases,
such as those found in glycomics, it becomes impractical to rely upon the general public to identify
and fix errors. Instead, automatic validation procedures must be used to assess incoming data.
Ensuring syntax validity for a database can be achieved by using various automatic checking
algorithms. Each record in the database must be checked against ontologies and vocabularies,
which reduce database redundancy by limiting data to canonical representations. Within the field
of glycomics, a good example of the practice of maintaining syntax validity is the use of well-
defined sequence formats, which can be checked automatically against a well-defined grammar.
Context validity is significantly more difficult to maintain automatically in a database. Al-
though a record may have valid syntax, the data that it represents may not be contextually correct.
Context checking is a non-trivial task to automate; historically, the best approximation to this was
achieved by peer review of the data. The feasibility of creating an automatic checking algorithm
for context validity is examined in this thesis.
To better understand context validity, an example using the English language can be used. The
sentence fragment “I can have a cheeseburger?” makes sense with respect to its syntax, following
the appropriate lexical and grammatical rules. However, when placed within a context — “Two
things are infinite: the universe and human stupidity; I can have a cheeseburger? I’m not sure about
the the universe.” — the sentence fragment no longer makes sense. Context validation assesses
the fragment against its neighbouring data, and determines whether this new data fits with the
existing data.
1.3 Summary
The study of glycans as post-translationalmodifications is an area that is ripe formany discoveries,
especially given the links established between carbohydrates and much functionality in biologi-
cal systems. The use of bioinformatics in this area has been hampered by the lack of generally
available and well-curated databases. Unfortunately, obtaining such databases requires a signifi-
cant investment of money in the curation process. The open curation model can provide similar
results, but extra technology needs to be in place to compensate for the lack of human review of
database entries. It is as part of a database review procedure that the algorithms in this thesis have
been developed — to allow for an automated check of the context validity of structures.
Within this thesis, Chapter 2 introduces the biosynthesis of glycans and the biological basis for
context validation. The algorithms for data verification and validation, as well as details about the
developed software, are found in Chapter 3. Chapter 4 introduces the main results from the thesis
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and provides an estimate as to the size of the glycome. The work done to establish the distributed
component of the EUROCarbDB database comprises Chapter 5. Chapter 6 summarises the full
thesis, and provides an outlook for future developments in this field.
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Chapter 2
≈
Biology of structural
verification
T
HE QUALITY OF DATA IN A DATABASE can be evaluated by examining two key inherent
properties of the data. The first critical property of the data is syntax validity. Lexical
errors in sequences must be minimised, with facilities provided to ensure that the entered
data matches what the depositor intended to enter. Syntax validity can be ensured using lexical
parsers, the description of which is beyond the scope of this thesis.
The second critical property of the data is context validity. Despite syntax validity, there is no
guarantee that the data is correct with respect to — or in the context of — other content in the
database. Although the responsibility of entering contextually correct data lies largely with the
depositor, automatic checks can be performed to evaluate each new sequence to see how well it
fits into its particular context. For new data that is not closely associated with existing data, the
onus is on the depositor to justify its addition to the database.
To check context, new sequences must be evaluated against the currently known sequences for
the biological source in question. The natural metric for how well one sequence is associated with
another is sequence similarity. It is not possible to use a naive alphabet-based sequence similarity
metric against a generalised glycome-wide sequence set since there is no guarantee that the known
sequences themselves are similar. In fact, the use of any method to check syntactic similarity will
always fail in the presence of protein sequence family heterogeneity. Basic biosynthetic pathways
are generally conserved across sub-systems within a glycome; with this in mind, a sequence sim-
ilarity algorithm that compares sequences against the current biosynthetic pathway knowledge
base has been developed, and forms part of this thesis.
It is important to clarify that any glycome discussed here is not a complete reference glycome.
Since the methods of regulation of the biosynthetic pathways leading to glycosylation have not
been fully elucidated, no single set of sequences can be said to represent perfect knowledge about
the glycosylation occurring in a particular biological system. We know neither the end sequences
nor the mechanisms of synthesis. In a practical sense, the glycome represents only the set of
sequences that have been deemed interesting enough by researchers to both characterise and enter
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into a database.
The current glycan biosynthetic knowledge base is codified within pathway rules, which de-
termine the order of action of a series of enzymes on various substrates to gain end products. A
simplified model of enzyme reactions — in which each enzyme reaction can be modelled as a
linear application of substrate, donor and product — is used for this study.
Biosynthetic pathway information in the glycan space has traditionally found limited use in
bioinformatics. Informally, it supplements incomplete data when performing sequence assign-
ment. General explorations of the glycan space have also been undertaken [39], but no commonly
accepted number that can act as a measure of the diversity of human glycans has been established.
A number of rough estimates have been made — from 500 structures [40], to tens of thousands
[41] to 10-104 times larger than the proteome, which is conservatively estimated at 470,000 glycan
structures [10].
2.1 Biosynthesis of glycans
Unlike proteins, the biosynthesis of glycans does not follow a template-based model [1]. The
process of glycosylation is complex, with many factors affecting the end glycosylation products.
Glycan biosynthesis occurs primarily in the Golgi apparatus, where the glyco-active enzymes
have their effect. There are several families of glyco-active enzymes: the glycosyltransferases (EC
2.4.x.x), the glycosidases (EC 3.2.x.x), sulfotransferases (EC 2.8.x.x) and phosphotransferases (EC
2.7.x.x). The spatial location, competition between, and concentration of these molecules (together
with substrate and donor concentration) are all factors in determining the end glycosylation prod-
ucts for any system.
Glyco-active enzymes (also known as glycogenes) are regulated on the transcriptional level.
A subset of the genes is expressed across all tissues, while the rest (notably those responsible
for non reducing end terminal diversification) are expressed on a tissue-by-tissue basis [41, 42].
This difference in expression accounts for some of the glycans’ structural diversity. Tissue-specific
expression also correlates with functional groupings of tissues, suggesting that the synthesis of
certain glycan structural features is relevant to the function of the tissue [43, 39].
Glycosyltransferases and glycosidases are bothmembrane-bound proteins that build and prune
glycan structures, respectively. Glycosyltransferases catalyse the transfer of a monosaccharide
unit, typically from a donor molecule to a defined substrate acceptor. The donor molecules are
usually sugar nucleotides, such as UDP-glucose, UDP-galactose or UDP-GlcNAc.
Glycosidases degrade glycans through the hydrolysis of a glycosidic bond, and have varied
specificities. Glycosidases can be specific to both anomeric or monosaccharide conformations.
Degradation of glycans allows structures to be remodelled, exposing different epitopes to change
the function of the glycosylation, as well as modifying the action of any further glyco-active en-
zymes by altering the target substrates.
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Glyco-active enzymes are highly variable in the reactions that they catalyse. It is not sufficient
to assume that a glycosyltransferase will catalyse a single reaction with a single substrate, nor
does the absence of a glycotransferase directly imply the absence of the linkage in the synthesised
structure. Linkages are redundantly coded in different transferases, and a transferase can also
catalyse different linkages. Substrate specificity and donor availability both play parts in deciding
which reactions are catalysed by a particular glyco-active enzyme. Although the multitude of
enzymes catalysing a linkage can imply redundancy along biosynthetic pathways, the redundant
genes may not be expressed in the same tissue, resulting in non-redundant expression of linkage
catalysis capability.
Gene expression A subset of genes was found to be differentially expressed in different tis-
sues in a PCR study of expression patterns [42]. Of 67 genes, only 35 were expressed in all tis-
sues. Genes that were only partially expressed across all tissues were indicative of regulation
at the transcriptional level. Of particular interest, all the genes responsible for the catalysis of
the GlcNAc(β1 → 6) ⇒ Gal and Fuc(α1 → 3/4) ⇒ GlcNAc disaccharides are not expressed in
all tissues, suggesting some regulation of branching on the transcriptional level. Most of the di-
sialylation genes (ST8SIA) are expressed on a per-tissue basis, while the tissue distribution of the
core Glc and GalNAc transferases suggests that each gene may code for different substrate speci-
ficities, regulated on the transcriptional level.
After protein synthesis in the endoplasmic reticulum (ER), proteins are modified as they pass
through the Golgi apparatus. The Golgi apparatus is arranged as a series of cisternae (see Fig-
ure 2.1), in a stack-like formation, with inter-cisternae movement achieved through vesicular
transportation.
There are two theories as to the arrangement of the glycosylation machinery within the Golgi
apparatus, according to the two current models of Golgi maturation [44]. One maturation model
anchors glyco-enzymes in the Golgi, with the glycosylation substrate being transported between
cisternae via vesicular transport. The other model localises the proteins to be modified in the cis-
ternae, transporting the glyco-enzymes in a retrograde fashion back up the Golgi stack. Regardless
of which model is correct, both imply a compartmentalisation of the enzymes, resulting in the se-
quential application of enzymes to proteins that are to be modified. Complexes can be formed
to further cement the ordering of the application of enzymes [45, 46, 47], which ensures their se-
quential application through their proximity both to each other and to the target glycosylation
substrate.
Beyond transcriptional regulation, regulatory mechanisms are required to account for the
structural diversity of glycans. Within a single tissue — and indeed, even on a single protein
— glycosylation is not necessarily uniform. Despite this, there are core structural motifs shared
amongst these structures, suggesting that this micro-heterogeneity is controlled from within the
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Figure 2.1: The Golgi apparatus is a series of cisternae, arranged from cis to trans.
Protein cargo moves from cis to trans, and various enzymatic treatments are applied.
As glycans pass through the Golgi apparatus, enzymes are applied sequentially, re-
sulting in a gradient of increasing complexity of glycans.
Golgi apparatus. Alongside the compartmentalisation of the various enzymes, donor concentra-
tion and the availability of precursor substrates all play a part in the production of the diverse set
of structures.
Donor concentration plays a significant role in the regulation of glycosylation. The interactions
between donor concentration, substrate availability and enzyme efficiency can lead to sophisti-
cated glycosylation behaviours. One such example is the effect of N-Acetyl-D-glucosamine (Glc-
NAc) concentration on the branching behaviour of N-glycans. Branching on N-glycans displays
an ultrasensitive relation to hexosamine concentration [8], an increase in the concentration of Glc-
NAc residues results in an increase in branching, thanks to the differing specificity and substrate
competition behaviour exhibited by the relevant enzymes. As a result of this ultrasensitivity, gly-
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cosylation profiles can be modified relatively rapidly during the cell life-cycle, providing a finer-
grained control mechanism for the regulation of glycosylation. Donor concentration can in turn
be regulated in earlier pathways such as the fructose or mannose pathway (KEGG pathway 51).
In addition to these regulatory mechanisms, other factors have an impact on the degree and
type of glycosylation. Protein conformation plays a role in determining the specificity of enzymes
(such as GALNT5 [48]) to particular substrates, by means of sequence recognition, patch recogni-
tion, and changes in the accessibility of the oligosaccharide substrate. Since it is possible that the
glycosylation on distinct and structurally different proteins can occur in parallel, the recognition
of protein [49] or lipid substrate as part of the acceptor substrate offers a possible explanation for
the heterogeneity in glycosylation profiles across proteins being glycosylated at the same time. In
addition, since glycosylation can affect the conformation of proteins [50], it is plausible to posit
that any glycosylation event may influence subsequent glycosylation. Since glycosyltransferases
compete for substrates, it is possible that other proteins being glycosylated in the vicinity may
affect the glycosylation of a protein by preferentially using up donor molecules, leaving it with
only lower-affinity glycosylation reactions.
Defects in the glycosylation machinery commonly lead to a corresponding profile exhibiting
incomplete glycosylation [51]. That glycosylation is exhibited at all suggests that there is no gly-
cosylation quality control mechanism in the Golgi apparatus, implying that the partially glycosy-
lated substrates will remain available in the Golgi pipeline even if essential glycosylation is not
completed. Genetic defects in the glycosylation machinery are known as CDG, and have been
reviewed extensively [10].
The specificity of enzymes varies — from the previously mentioned conformation-specific
GALNT5, to enzymes that recognise a disaccharide structural feature (such as B4GALNT1/2, syn-
thesising the SDα epitope), or less specific enzymes, such as glycosidases.
Based upon this regulatory information, the glycosylation machinery can be generalised into
two regulatory categories. The first combines transcriptional regulation, compartmentalisation,
and enzyme specificity to provide coarse control over glycosylation. The second uses finer-grained
control mechanisms such as donor concentration and compartmentalised substrate competition to
allow for temporal modification of the glycosylation profiles — especially for terminal structures.
Functional studies of glycosylation have been undertaken through the engineering of various
knock-out strains of mice [52] which exhibit both differing phenotype and changed glycosylation
profiles. Interestingly, the changes in glycosylation profiles between knock-out mice have either
been drastic, or simply changed the quantities of the exhibited structures. Drastic profile changes
have been associated with mice that knock out early stage glycosyltransferases in the pathway,
whereas knock-outs of the later-stage transferases (such as the decorative FUT enzymes) cause
more subtle changes. This lends credence to the concept of glycosylation being tuned at later
stages, with this secondary means of regulation being supplemental to the transcriptional level.
Depending on the nature of the change in expression levels for a particular glycosyltransferase,
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different effects can be seen. Underexpression of an enzyme will most likely result in a cascade
effect, in which other enzymes requiring substrates catalysed by this particular enzyme cannot
function. This results in a whole family of structures not being synthesised. Overexpression,
or even introducing new enzymes into a system, may not necessarily change the glycosylation
profile. The absence of donor residues, or the limited amount of available substrate, may conspire
to reduce the effect of changes in the enzyme’s expression level. Generally speaking, there are too
many factors involved to be able to gauge the effect of overexpression.
2.2 Bioinformatic analyses of pathway information
Given the inherent complexity of the glycosylation machinery, and the subtlety of the operation,
this area is ripe for rigorous bioinformatic analysis. In particular, it is practical to take a pluralistic
systems biology approach to analysis. The study of glycomics data has thus far not been generally
applied in the field of systems biology — primarily because there is no well-defined algorithm
for predicting glycosylation from the varied set of inputs that regulate it, and as such, we do not
know all the forms of glycosylation which may exist. Similarly, there is no clear understanding of
the functions of glycans on their own; further study is needed to elucidate this in a generalised
way.
All bioinformatic analyses regarding biosynthetic pathway information has thus far focused
on using this data to predict N-linked glycosylation profiles. N-linked glycosylation has been the
most well-studied of glycosylation types, and all structural databases reflect this bias. The wealth
of data surrounding N-glycans makes this family of structures a logical target for buildingmodels.
The most sophisticated modelling method for glycosylation is the mathematical model ap-
proach [53, 54], which models the cisternae in the Golgi as a series of chemical reactors with a
constant flow rate, using differential equations to determine the success of a particular reaction.
These models have been used to predict the whole glycosylation profile in response to modifica-
tions to donor and enzyme concentration. The modelling has been undertaken by groups looking
to produce uniform glycosylation profiles by searching for the optimal enzyme and donor concen-
trations. The utility of this method is dependent on having good data about the enzymes being
modelled, as it involves in silico fine-tuning of the glycosylation machinery to produce the desired
structures.
In combination with gene expression data, biosynthesis data can be used to attempt to predict
glycan structure profiles [39]. By considering the co-occurrence of disaccharides in structures,
donor-substrate reactions can be clustered together. The clusters of reactions reveal classes of
structures as well as biosynthetic pathways. By finding the structures with the closest number
of common donor-substrate pairs, the best predicted structures can be suggested. A limitation of
this methodology is that the fine-tuning of the glycan structures is not taken into account — the
suggested structures will be representative of the larger-scale regulation of glycosylation.
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Estimates of actual glycan diversity are quite difficult tomake. Upper bounds on the total num-
bers of structures can be provided, through basic combinatorial methods, but the actual number
is further limited by certain biochemical factors. Currently, the optimal way to estimate the size
of the glycome is to extrapolate from existing databases, which are an approximation of what is at
the very least biosynthetically possible.
There are two approaches to the classification of glyco-active enzymes — functional and se-
quence. Functional classifications come in the form of EC numbers — with 295 glycosyltrans-
ferases and 189 glycosidases identified. Because a single enzyme can have many different func-
tions, it is possible for more than one EC number to be assigned to a particular gene. Sequence
classification, exemplified in the CaZY [55, 56] classification system, examines the polypeptide se-
quence similarity of enzymes. This classification does not necessarily have a functional relation,
and is of limited use unless studying the actual enzymes.
2.3 Bias in existing structural databases
Current knowledge about structural diversity can be obtained by examining entries within ex-
isting databases. Over the past 20 years, a number of structures have been deposited into the
databases in order to facilitate the creation of these global knowledge bases. The vast majority of
the data has been created ad hoc; there have been no concerted efforts to provide whole glycomes
for any one system. The diversity of structural sources inherent in the databases has a number of
implications. The most important is that it is difficult to draw any conclusions through analysis of
the databases as to the completeness of any one set of structures.
Because a number of techniques have been used to elucidate the structures found in databases,
it is unknown whether the structures are representative of the complete glycome or are simply the
most easily qualifiable structures. A large amount of general biosynthetic pathway knowledge
has been used to assign sequences, so the entries in the databases may also be biased towards
structures which fit into known biosynthetic pathways.
This possible bias in the sequence databases makes it difficult to perform any meaningful
bioinformatics in the realm of glycomics. Any conclusions drawn must be treated with great
skepticism — if biosynthetic pathways are in agreement with sequence data, this may provide
insight less into the actual extent of the glycome, and more into the use of pathway information in
sequence assignment. Steps can be taken to mitigate this, such as extensively verifying literature
and comparing independently validated curated databases.
2.4 Human system as a model system
There are a number of estimates as to the size of the human glycome. A lower estimate of the
size of the human glycome is 500 [40], which is less than the number of human sequences in most
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databases. Higher estimates put the number of glycans at 10-104 times larger than the proteome—
at a conservative estimate 47,000 – 470,000 glycan structures [10], tens of thousands of structures
[41], or thousands of times more complicated than the genome.
The human system has been chosen here as the target system for data analysis due to the
congruence of the availability of data in terms of genes, expression, sequence and structure. This
wealth of information is a result of this system being well studied. Although the completeness
of glycosylation profiles for various sub-systems varies across the whole system, we can still use
this data to draw general conclusions about the nature of glycosylation in humans, with certain
caveats. A number of glycan classes are expressed— from the sub-types of N-glycan, to O-glycans
and proteoglycans. This diversity of expression also makes this a rewarding system to analyse.
Currently, the best approximation for a human glycome will come from using a subset of the
GlycomeDB [57] to obtain the structures. To verify the data, a set of independent structures are
obtained from GlycoSuiteDB [37], which is current to 2005.
2.5 Summary
The biosynthesis of glycans in the ER and Golgi is a complex process, involving many sub-
systems, and dependent mechanisms. The system can be better understood and analysed by
using biosynthetic pathway data, which can be considered representative of all collected data
in databases, and possibly even the glycome as a whole. Pathway data may therefore be used as a
surrogate for the complete database in order to perform contextual validation. This must be done
cautiously, however, as inherent biases may affect the efficacy of the validation; pathway data
must always be verified. Assuming that biosynthetic information can be encapsulated in pathway
data, it also becomes feasible to estimate the size of the glycome from this information.
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Chapter 3
≈
Methods
T
O BE ABLE TO VALIDATE SEQUENCES against a surrogate for contextual information — i.e.
pathway data, we need to establish the integrity of the pathway data to see whether it
can be used to judge the novelty of structures entered into the database. This involves
verifying that the enzymes can code for the synthesis of all structural features. Subsequently, the
pathway data needs to be evaluated for its ability to support the synthesis of these features. Any
differences in the support of enzyme and pathway data of the complete feature set points to new
structural features which are not covered by current knowledge bases, or possible errors in the
structures that need to be resolved. Once the pathways have been verified, a metric to convey the
differences between the candidate structure and the current knowledge base can be obtained, and
the size of the glycome estimated.
This complete analysis can be broken down into two steps — data collection and verification.
Data collection and verification must take place independently for the enzyme data and pathway
data.
3.1 Enzyme data
3.1.1 Data collection
Data collection for enzyme data was undertaken using a manual curation process. Initially, a list
of enzymes was obtained from the KEGG Glycan [30] resource. Each gene name was associated
with a particular donor and acceptor substrate known to catalyse a reaction and was generalised
as: Donor(anomer linkage) ⇒ Substrate. Since different identifiers were being used to identify
each of the genes from the various resources, the names were normalised to use a generalised
identifier scheme based upon the Entrez GeneID. As the rate of enzyme discovery is low, it was
deemed unnecessary to automate this initial data collection step. The data collection yielded a
set of disaccharide reactions with broad substrate specificities — often recognising only a single
residue on the target substrate. To supplement this data, the GGDB [58] was sourced to obtain
more reaction substrate specificities. Once again, a manual curation process was used to obtain
this data, capturing as much substrate information as possible. It was originally envisaged that
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further substrate specificity information could be obtained through a literature survey. To this
end, a web-based curation tool was developed to allow for the rapid entry of data, whilst also
allowing for simple searching of existing data.
For the initial data collection phase, a tabular approach was used, based upon a spreadsheet
application. This obviated the need for further software to be developed and maintained while
the data being collected was still undefined. Once the data set reached a satisfactory size (approx-
imately 50 entries, enough to understand the nature of the data), a more rigorous format for the
storage of data was decided upon, and a database system designed to hold the data. Sequences
for donors and substrates were initially encoded in the International Union of Pure and Applied
Chemistry (IUPAC) condensed format [59] (GlycoSuiteDB variation) with no support for repeat-
ing units or uncertainty in sequence elements. Sequence encoding was moved to a variation of
GlycoCT [60], to permit comparison with various databases of structures. Data were designed to
be exported and imported from the database using a simple markup to identify the fields in the
exchange document. For this purpose, a XML file with versioning for reproducibility was used.
3.1.2 Data verification
Group 1 Group 2 Group 3 Group 4
Genetic information Y N Y N
Database verification Y Y N N
Table 3.1: Reaction classification. Reactions can be classified into one of four groups,
depending on the availability of genetic information and the status of database verifi-
cation.
To verify the enzyme data, reactions were placed into four groups (Table 3.1). Reactions that
are backed up with genetic information (Groups 1 and 3) are defined to be correct, whereas reac-
tions for which evidence exists only in databases (Groups 2 and 4) are deemed to be potentially
inaccurate. The potentially inaccurate reactions are the most important to examine to evaluate the
source of the inaccuracies.
For a reaction to be validated using the database alone, the product of the reaction needs to
have been observed in real structures. A reaction can be observed if the resultant disaccharide
which the reaction catalyses is found in a structure. For example — if the Gal(β1→4)GlcNAc
linkage is found in the database, this provides evidence for the correctness of a Gal(β1→4) ⇒
GlcNAc reaction. All structures need to be searched for the presence of the disaccharide, so all
disaccharides need to be generated for the structures.
To obtain the disaccharides from the database, a simple breadth-first tree traversal — in which
the child residues for a particular residue are enumerated — is performed on each structure in the
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Figure 3.1: Generation of disaccharides from a structure. A traversal of each of the
parent-child residue pairs is performed, resulting in a set of unique disaccharides and
the frequency of their occurrence in the structure.
database (see Figure 3.1). The identifier for the structure is also assigned to the disaccharide to
allow the data to be traced back to its originating structure. This step allows for the generation
and counts of all disaccharides for a structure. The disaccharide lists for each structure are then
combined with the disaccharides for all other structures. Multiple occurrences of a particular
disaccharide in the one structure are only counted once, since there is only one structure that
serves as evidence for that particular disaccharide (see Figure 3.2). All the disaccharides for a
particular set of structures can be listed in this way.
Since the database itself is unreliable, we need to perform filtering on the generated data to
ensure that the set presented contains only disaccharides known to occur in a minimum number
of structures. For the purposes of this analysis, the filtering is set to a disaccharide appearing
in a minimum of six structures. After this first filter, further filtering occurs whereby disaccha-
rides from structures that have been entered into the database incorrectly are removed. This is
a manual curation step, and is largely dependent on further meta-data on the original structure
being available for examination. Secondary filtering was performed for data coming from the
Glycosciences.de database and Carbbank [34], as the reference information was readily available
for examination. For certain disaccharides, structures were examined based upon their original
papers. From here, errors in sequence were looked for, and if found the originating structure was
deemed invalid. Errors found in sequences ranged from incorrect transcription of data from the
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Figure 3.2: Collating the set of disaccharides from a set of structures. The disac-
charides are generated for structures A-F, with the individual frequency for each of
the disaccharides found listed. The totals are derived by counting the non-zero fre-
quencies for each disaccharide across all structures. A frequency greater than 1 for
a structure is not counted more than once since the structure only provides a single
piece of evidence that the disaccharide exists in nature.
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paper, incorrect encoding of the sequence within the paper to incorrect assignment of sequence as
a result of flawed analysis. The incorrect assignment of sequence within the paper was determined
by examining the techniques used to elucidate sequence, and judging if there is sufficient data to
make the claims as to the existence of the structural feature. At a bare minimum, for a disaccharide
deemed to be new, a technique which could unambiguously identify the structural feature was re-
quired to be used as evidential material. This evidence could include lectin specificity, glycosidase
specificity, the presence of diagnostic ions within MS data, or the full characterisation of the struc-
ture using NMR. Often, structures were assigned to have a particular sequence with insufficient
evidence to support the assertion. Appendix A lists all the structures from Glycosciences.de that
were determined to have errors associated with them.
Following these filtering steps, a manual comparison step was performed to determine which
of the disaccharides and reactions were actually observed, and which were database artefacts. The
results can be found in Chapter 4.
3.2 Pathway data
3.2.1 Data collection
Pathway name
N-Glycan biosynthesis
High-mannose type N-glycan biosynthesis
N-Glycan degradation
O-Glycan biosynthesis
Chondroitin sulfate biosynthesis
Heparan sulfate biosynthesis
Keratan sulfate biosynthesis
Glycosaminoglycan degradation
Lipopolysaccharide biosynthesis
Peptidoglycan biosynthesis
GPI-anchor biosynthesis
Glycosphingolipid biosynthesis — Lactoseries
Glycosphingolipid biosynthesis — Neo-lactoseries
Glycosphingolipid biosynthesis — Globoseries
Glycosphingolipid biosynthesis — Ganglioseries
Table 3.2: Names of pathways used in the analysis of pathway data
Collection of pathway information is significantly less complex as the KEGG pathway resource
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is the primary source of information for this data. A File Transfer Protocol (FTP) download allows
the data for all the different pathway classes to be obtained. The biosynthetic pathways available
from KEGG are listed in Table 3.2.
Informatically, a representation of a pathway can be realised by considering it as a state ma-
chine. A state machine is a graph in which the nodes represent states, and the edges represent
transitions between states. For the purposes of pathways, the substrates and end products of re-
actions are nodes, while the enzymes involved are edges. Within the downloaded data files from
KEGG, the end products and substrates are stored as KEGG structure identifiers. To translate the
KEGG identifiers to actual sequences, GlycomeDB [57] was used to obtain the sequences in Gly-
coCT [60] format. Since each reaction and substrate pair appears only once in a pathway, it was
sufficient to use the reaction definition from the enzyme database, and annotate it with a path-
way identifier to indicate that it is part of a pathway. Starting from the smallest structures in a
pathway, we can recreate the pathway state machine by looking for all reactions with the pathway
annotation, matching end products with substrates.
3.2.2 Data verification
Pathway verification is an involved process. Essentially we wish to verify whether the structures
found at steps along the pathway can be found in nature, and that all structures in nature can
have their biosynthesis explained by a pathway. Simplistically, we can examine the structures
in each state of the machine, and verify that there are structures which cover that part of the
state machine. This method fails for coverage of the entire pathway, since there are intermediate
structures which may not have been characterised experimentally, although structures later in the
pathway may exist. This method also only gives a simple characterisation of the data deficiency
— it can only characterise the presence or absence of the data. Ideally, an analysis would better
characterise the pathway data with respect to known structures to identify any potential new
biosynthetic pathways.
One convenient way to calculate the difference between the known structures and what is
defined in the pathway is to calculate the composite structure map —with counts for the number
of times a particular structural feature is seen— and then to subtract the largest pathway from this
larger composite structure (Figure 3.3). Although simple, this methodology does not differentiate
between the extensions that can take place along different points along the pathway, and does not
allow individual pathway extensions to be identified.
To allow for individual extensions to be accounted for, one can take the largest structure from
a pathway, and calculate intersections of this structure with all other structures (Figure 3.4). Any
structure which contains the largest structure as a sub-structure can be considered to have an
extension to the defined pathway of some sort. By storing the sequence of each of the extensions,
one can list the extensions to amaximal pathway individually. This method is flawed as it does not
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Figure 3.3: Resolving a single structure using pathway elements. The query structure
is compared with the largest tetrasaccharide from the pathway structures (β). The two
residues GlcNAc and Man are identified as extensions (α) on the largest pathway ele-
ment, while the matched tetrasaccharide is marked in grey. This basic step identifies
a single extension on the largest element of a pathway, and needs to be expanded so
that it can identify multiple extensions along the pathway.
Pathway elementsStructure set
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Figure 3.4: The largest pathway element (γ) is compared with all structures in the
structure set. Any extensions found using this algorithm are marked in red. The fuco-
sylated di-GlcNAc structure (α) has not been found to have an extension, even though
the fucosylation occurs on a substrate which has not been identified as fucosylated on
the pathway elements (β).
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account for extensions occurring exclusively at earlier points (such as branching decision points)
along the pathway. A method that discovers these individual extensions occurring along any
point along the pathway is needed.
To discover the full multitude of extensions, we need to take each structure from the database,
find the largest pathway structure that is smaller than that structure, and then collect the exten-
sions to the pathway structure — including the points at which the extensions are attached. This
process is repeated for all of the structures in the particular subset of data that is being examined.
After this, the additions at each unique attachment point are combined into one structure, giving
the full set of extensions at the location in the pathway where the attachment point is exposed.
The path from this point to the root of the glycan is called the root path. By merging only the root
paths and pathway extensions together, we can create a composite structure that contains only
the extensions along the complete pathway. This algorithm is described in Figure 3.5. Since each
of these activities is a non-destructive merging activity, it is possible to keep a tally of how many
structures each of these extensions appears in. This can be used later to filter out any structural
features which result from errors in the data, by removing low-abundance sequence noise.
Following generation of the new composite extension maps, each extension that has not been
covered by a pathway needs to be resolved, and examined to see if it represents a potential new
pathway. The automatically converted pathway data from KEGG is not complete — certain ex-
tensions involving repeat structures are not encoded into the pathway data, and some elements
may not have been translated correctly from the KEGG data into the local pathway data. At the
end of this process, it should be possible to determine the data completeness and the extensions
required so that it covers a greater number of structures.
When evaluating the coverage of the pathways, it was convenient to consider fucosylation, sia-
lylation and sulfation events to occur outside the pathway mechanism, as these structural features
occur at many points along the pathway. They are essentially modifications upon the backbone of
the structure, whose distribution needs to be examined separately.
3.2.3 Mathematical operators for glycans
Glycans are naturally represented as graph-like constructs (see Section 3.4). For the structural
analysis of glycans, a set of basic graph-like operations is of great utility. The operations that are
most useful are those related to set theory. Union and intersection form the basis of the addition
and subtraction operations upon glycans respectively.
Unions of glycans can only be performed when they have at least one residue at a particular
position in common. For example, this could mean that both sugars share a common root residue.
The union operation is actually a special case of a traversal operation, where each node is visited,
and any children that are not part of the first addend are cloned and attached to the first addend,
as shown in Figure 3.6. A node cloning operation is a deep cloning, and all descendants of the
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Figure 3.5: The final algorithm for detection of extensions along the pathway. Each
structure from the structure set (α) is compared with the largest pathway element
from the pathway elements (γ) that are contained within the structure. From this, the
extensions are identified, as well as the path back to the root, which is used to identify
the location where the extension is applied. A union is then performed on the path
extension set (β) so that a single extension labelled composite structure is generated.
This composite structure (δ) identifies new extensions along the pathway, as well as
structural features which are synthesised at points earlier in the pathway (%).
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Figure 3.6: The union of structures (α) and (β). A parallel traversal is performed on
structures (α) and (β), where the children of each node are compared. Any children
not found in both sugars are added to the resultant sugar (marked out in red) so that
the resultant structure contains all structural features found in structures (α) and (β).
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Figure 3.7: Subtraction of a sugar. Paths A.1, A.2 and B.1 are generated from struc-
tures A and B by performing a traversal from leaf to root. Paths A.1 and B.1; and
A.2 and B.1 are traversed in parallel to compare nodes. The residue marked in red is
deemed to be unique to the first structure, and the sub-tree rooted at the residue is
taken as a result. On the second traversal, this same residue is found, but is not a new
result since it is already part of the result set.
node are added. In all cases, the sugar is defined as an edge-labelled tree structure — where each
individual edge is unique. Circular structures are not abundant enough in human data to warrant
adding support for these types of structure in the analysis. By performing a union across two
graphs, the labels on the edges may not necessarily be unique (although in combination with the
node they attach to, they form a unique tuple), resulting in the need to modify basic tree traversal
algorithms to handle this multiplicity. In order to simplify the process of performing the union,
glycans are restricted to those forming only acyclic graphs, with a common label on both the root
nodes.
The algorithm for calculating the intersection of two glycans is essential. A greedy algorithm
is used, growing the maximal common sub-tree from the root of the first operand. Each of the
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paths from the leaves to the root of the structure is reversed, and is followed in parallel down the
other operand. Any nodes that are not members of the path are excluded from the intersected
structure. The algorithm for subtraction (Figure 3.7) is an extension of the intersection algorithm,
where sub-trees originating from the excluded nodes are returned as the non-common nodes.
3.2.4 Glycosidase modelling
Glycosidases are not explicitly modelled within the system. Since each of the glycosyltransferases
catalyses the addition of only a single residue onto a substrate, it is sufficient to model the activ-
ity of glycosidases by considering that the action of a particular glycosidase is equivalent to the
inaction of the complementary glycosyltransferase. Also, given that the main pathway in which
glycosidases are active is within the N-linked pathway, where mannose trimming takes place, it
was deemed unnecessary to model the action of glycosidases. Within pathways, all substrates that
are the end product of the action of a glycosidase are already modelled within the system. Since
the algorithms are designed to find extensions upon the pathway, this provides us with enough
information to find any possible extensions from this point onwards.
3.3 Validation of sequences
The actual algorithm for the validation of sequences is a specialisation of the algorithm to vali-
date pathway data against the database. Only a single structure (instead of the entire database) is
checked against the set of pathways. Any parts of the structure that are not covered by the path-
way are deemed to be one of several defined branch extensions derived from the results section. If
any residues cannot be accounted for through the pathway or branch extension, then the structure
is deemed as potentially invalid for the context.
3.4 Software models and implementation
There are two object models used to realise the algorithms. The first is a simple data storagemodel,
used to maintain the integrity of the enzyme data. The second model is a set of programmatic
entities which can be used as a toolkit to perform these analyses.
3.4.1 Model for data storage
The storage model used for enzymes is simple, with weak relationships defined between the enti-
ties. The entities can be broken down into Enzymes, Genes, Reactions and References. The UML
diagram (Figure 3.8) explains the relationship between these entities, and the fields that they each
have.
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Figure 3.8: UML class diagram for the storage model of enzymatic data. Data types
are not shown for fields within the model. The model was designed to allow for a
generic collection of data concerning enzyme specificity on the protein level. In a
practical sense, the model was used more to link the gene information to the reactions
that each gene may catalyse.
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3.4.2 Software model for analysis
The analysis model is based on the manipulation of a series of classes that model the sequence of a
single glycan. As with any toolkit for analysis, the flexibility of the tools used is critical. Priorities
in the development of the software were maintaining the modular functionality of the toolkit, as
well as procedures to ensure reproducibility of results.
3.4.3 Software implementation for analysis
To perform the data analysis, custom software was written. A conscious decision was made not
to support the modelling of all the structural features found on glycans, as this adds complexity
to the software, which can only be used in limited situations. Instead, the software toolkit was
designed to be flexible enough to perform a variety of structural analyses. In addition, the toolkit
was designed so that simple scripts can control the execution of analyses, and so that all results
are easily reproducible, even when faced with changing data and algorithms.
Multiple namespaces
Since this project was in part a data integration project, and data could come from a number of
sources, residues on the sugars were given identifiers which were de-coupled from their name
in any particular sequence format. So this means that the name for a residue can be obtained in
GlycoCT, Glyde [61] or IUPAC condensed at runtime. This was of particular benefit for writing the
test suites for the software — all test cases could be written in IUPAC condensed format, and the
same program logic would be used as if the sequences were written using GlycoCT. In addition,
tests could be made on residue names across different namespaces, according to what best suited
the program being run. For example, tree traversal algorithms remained the same while a single
namespace switch would result in the algorithms working on residue super-classes.
Reporting modes
A sophisticated rendering system was developed to allow for the generation of interactive reports
on the data. Rich reporting was key to the project, as one of the main challenges with interpre-
tation of resultant data is the large volume of it. Intermediate composite structure results had
more than 100 residues within structures, each with several annotations on the residues. Exist-
ing rendering methods only provided static rendering of sequences — any further annotation on
sequences could not be rendered as part of the report.
The central component of the report-rendering engine is a basic structural layout engine and
various plug-in rendering engines. The basic structural layout engine was used to provide a sim-
ple layout of the structures, so that all structural features could be observed. It was not a priority
to produce images that matched with the established layout of sugars, so drawing features like
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fucosylation as a stub residue was not implemented. The most important rendering engine devel-
oped was the Scalable Vector Graphics (SVG) rendering engine, which produced vector graphic
rendering of the sugars. By using XML-based rendering, it was also possible to carry through
the annotation of structures into the report document itself through the class attribute of image
elements. This document could then be used to generate static images — in Portable Network
Graphic (PNG) format for example — or could be embedded in an eXtensible HTML (XHTML)
page to act as a starting point for further exploring the data set in interactive reports.
The ability to explore the data set, and the rich reporting used during the analysis, greatly
aided in the interpretation of data. Any manual annotations on the data were saved, so that all
reports could be manually regenerated.
Unit testing
Due to the modular nature of software development, it was prudent to use a comprehensive set
of test suites to ensure that the core algorithms worked as expected, and that no changes in the
algorithms would change the results in any way — known as a regression. Each change set in the
core objects was associated with a test case, which allowed the added functionality to be tested, as
well as any regressions in functionality which may have been introduced by the addition of this
functionality.
Language choice
Ruby [62] is a powerful language, due to high level programming constructs andmeta-programming
features. The language itself allows for a semi-mathematical expression of algorithms, and is well
suited to the job of list processing and filtering — which is the basis of most of the algorithms
used in this project. Based upon the strengths of the language, Ruby was chosen as the language
in which to implement the software.
Web application
Part of the original plan for this project was to supplement the original enzyme data with man-
ually curated data from literature, in order to build a comprehensive database of all enzymatic
information. Although this part of the project was not used, a web application was built using
Ruby on Rails to assist in the maintenance of the data. Simple operations for the addition, dele-
tion and modification of entities were automatically generated, and then more complex reporting
pages were created.
In addition, some small applications were created to allow for exploration of data, and the easy
deposition of any new information. One tool looks at the enzyme coverage map for a particular
structure, another generates the full set of theoretical structures from a set of enzymes, and another
was developed to serve as a test for a completely graphical method of drawing structures. All
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these tools remain in an early stage of development, as they were designed primarily to aid in the
interpretation of the data.
Since the application logic is de-coupled from the presentation, it was simple to add pure
XML and plain text reports on the data in the database, which also allowed for more complex
functionality to be built up by mixing and matching existing functionality.
3.5 Summary
To develop a technique for automatic sequence validation with respect to context, a number of
verification methods needed to be established. For the biological system in question (Homo sapi-
ens in this case), enzyme and pathway data was obtained. Enzyme data can be curated from
various databases available on the internet, while pathway data is available from KEGG. Both the
enzyme and pathway data then needs to be verified. By comparing the enzyme and pathway data
with structures in the database, it is possible to gauge how well this data represents the sequences
within the database. The algorithms to perform this can be realised in Ruby, or any other suitable
high-level language. Once it is established that the pathway data is representative of the data in
the database, it can be used to validate new sequences in the context of the biological system, and
also to estimate the size of the glycome.
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Chapter 4
≈
Results
T
O VALIDATE STRUCTURES using biosynthetic pathway data, data was collected and veri-
fied from various sources. The verification of enzymes and pathways yielded a number
of results. Specifically, a number of key findings with respect to the correctness of enzyme
data and pathway coverage were established. Secondary investigations involving substrate anal-
ysis were also performed. After the verification process, it was possible to develop an algorithm
to perform automatic context validation, and an estimate of the size of the human glycome was
provided.
4.1 Enzyme verification
The enzymes curated from the data sources are shown in Section A.1 (found in Appendix A).
There are 136 distinct genes identified as being responsible for the action of glycosyltransferases,
which in turn have been associated with a total of 303 different reactions. Of these only 60 sub-
strate/donor residue and linkage groups are unique. This is a larger number of enzymes and
reactions than the KEGG analysis [39], which had only 98 enzymes and 42 reactions.
The enzyme reactions were compared with the 255 different disaccharides found in the human
subset of GlycomeDB. Table 4.1 lists the donor, acceptor and linkage combinations, highlighting
the entries where either no genetic information has been collected for a linkage, or where genetic
information has been found, but no structures with that particular disaccharide have been found.
A filter was applied to the disaccharide data so that only the disaccharides that have been found in
at least six independent structures are displayed. Applying this filter results in the total number of
disaccharides being reduced to 53. Linkages in green are supported by enzyme data, linkages in
black have no supporting structural data, linkages in grey are common structural errors, whereas
linkages in blue do not have any supporting enzymatic data. The literature used to support the
presence of these new linkages is listed alongside the disaccharides in Table 4.1.
Interestingly, the Gal(α1→3)⇒GalNAc reaction, falling below the tolerance level for inclusion
in the table, has been identified as a unique structural feature in carcinoma [74] and onmucins [75]
[76]. The Gal(β1→3)⇒ Glc reaction motif also falls below the tolerance level for inclusion in the
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Table 4.1: Human disaccharides derived from the database compared with collected
enzymes. Green linkages have both enzyme and database support, blue have only
database support and black have sonly enzyme support. Grey linkages have been
found to be database errors. Disaccharides occurring fewer than six times are filtered
out.
table, but has been found to exist in urine [77], although the structure may have originated in a
non-human system [78]. Similarly, the Gal(β1→6)⇒ Gal reaction has been detected in urine [63]
[64]. Since these structures may not be synthesised by the endogenous glycosylation machinery,
it may be prudent to exclude urinary glycans from any kind of future whole glycome analyses. In
practice, this may be hard to achieve, as this localisation data may not be stored in the database.
On the other hand, the GalNAc(β1→3) ⇒ GlcNAc reaction has not been found in any struc-
tures. The enzyme catalysing this reaction (B3GALNT2) has been characterised [79], but structures
containing this feature have not yet been found. EXT1 and EXT2 encode the GlcA(β1→4)⇒ Glc-
NAc reaction found in heparan sulfate, but there is no disaccharide data to support this. This is
due to the encoding of this linkage within repeat structures, which have been excluded from the
main body of the disaccharide analysis. The Man(α1→4)⇒ GlcN reaction (encoded by PIGM) is
present only in GPI anchor biosynthesis — the structures of which are not found in the structural
databases.
A subset of reactions is supported both by structures and by enzymatic information, but the
structures in which these motifs are found occur too seldom to pass the structure count tolerance
filter. The resulting disaccharides form transferases that take fucose as the acceptor substrate —
B3GALT1 (catalysing aGlc(β1→3)⇒ Fuc), LFNG andRFNG (responsible for the GlcNAc(β1→3)Fuc
linkage) are all under-represented in the database. The EXTL linkage GlcNAc(α1→4)GlcA) also
appears infrequently, even though it is found in the heparan sulfate biosynthesis pathway. This is
to be expected, given the lack of evidence for the linkages catalysed by EXT1 and EXT2.
The number of filtered human disaccharides (53) compares well with the number of reactions
collected from glycosyltransferase databases (60). Although a filter was used for this data, there
are still 11 reactions found in human structures that have not been associated with either enzy-
matic or pathway information. There are many more reactions that did not pass the structure
count filter, and without checking the references for all those reactions, it is not possible to pass
judgement as to whether these structural features are real, or whether they are artefacts. In general
however, the similar number of reactions that has been curated and generated indicates that the
size of the curated reaction set is of the right order of magnitude.
A summary of mammalian glycosyltransferases [11] can also be used to compare the com-
pleteness of the enzyme data collected. Comparison of the reaction matrix from this paper with
the results here indicats a number of discrepancies (Table 4.2).
4.2 Substrate elucidation
It became clear during the data collection phase that the substrate specificities for the enzymes
were not well established. This is largely due to the appropriate data not being present. To synthe-
sise the Sdα epitope, the GalNAc(β1→4)⇒Gal reaction requires the presence of theNeuAc(α2→3)Gal
substrate [80], and so the NeuAc residue should always be a sibling of the GalNAc residue — that
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Found exclusively in the Database Found exclusively in Summary
Fuc(α1→3)⇒ Gal GalNAc(α1→6)⇒ GalNAc
Fuc(α1→6)⇒ Gal GlcNAc(α1→6)⇒ GlcNAc
Gal(β1→6)⇒ Gal GlcNAc(α1→4)⇒ GlcA
Glc(α1→4)⇒ Glc GlcA(β1→4)⇒ Gal
Glc(α1→6)⇒ Glc Man(α1→4)⇒ GlcNAc
GlcNAc(α1→4)⇒ Gal Xyl(α1→3)⇒ Glc
GlcNAc(β1→4)⇒ Gal Xyl(α1→3)⇒ Xyl
GlcNAc(β1→3)⇒ GalNAc
GlcNAc(β1→4)⇒Man
GlcNAc(β1→6)⇒Man
NeuAc(α2→3)⇒ GalNAc
NeuAc(α2→6)⇒ GlcNAc
Xyl(β1→3)⇒ Xyl
Table 4.2: A comparison of lists of reactions found exclusively in collected data versus
a review paper.
is the NeuAc and GalNAc residues both share the same parent. To verify this, and to identify any
substrates which require the presence of a particular sibling, the sibling residues were counted. A
number of these siblings were identified, and can be considered as branching points on the struc-
tures. If a particular residue is almost always seen next to another residue, it can be assumed that
the pathway has an influence on the attached residue, one residue is required for the other to have
an action, or a combination of the two. If the relationship is not reflective, then the action of this
particular transferase is optional — and is equivalent to a branching step.
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Other sibling
67 total
423 total
118 total
423 total
Fuc(!1"2) sibling
Gal(!1"3) sibling
GalNAc(!1"3) sibling
76%
3%
12%
14%
27%
24%
85%
3%
Figure 4.1: Fuc(α1→2)Gal substrate. The pie charts show the number of siblings that
are found for each residue of each type.
Fuc(α1→2)Gal substrate See Figure 4.1. The Fuc linkage primarily occurswith no siblings (61%),
but whenever it is found at a position where branching occurs, it is as a sibling of either Gal or
GalNAc. The GalNAc linkage has a sibling 88% of the time, which is the Fuc residue in 85 of the
cases. Similarly, Gal has a sibling 79% of the time, which is primarily (76%) a Fuc residue. Within
pathways, the Gal(α1→3)⇒ Gal and GalNAc(α1→3)⇒ Gal reactions occur sequentially after the
Fuc(α1→2)⇒ Gal reactions. This data suggests that the reactions catalysing the GalNAc and Gal
linkage both preferentially act upon the Fuc(α1→2)Gal substrate, or that the galactosyltransferase
and GalNAc transferase may form a complex with the fucosyltransferase.
NeuAc(α2→3)Gal substrate See Figure 4.2. In 75% of cases where the GalNAc(β1→4)Gal dis-
accharide is seen in structures, a sibling residue to GalNAc can be found. A NeuAc residue
on the α2→3 linkage is the predominant (91% of total) residue to form a sibling to GalNAc.
The NeuAc(α2→3)Gal disaccharide occurs primarily at a non-branching linkage position, hav-
ing no sibling 93% of the time. Ninety-six percent of the NeuAc(α2→3)Gal linkage siblings are
GalNAc on a β1→4 linkage. Given these numbers, it is impossible to draw the conclusion that the
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Other sibling
NeuAc(!2"3) sibling
GalNAc(#1"4) sibling
65%
6%
0.5%
10%
63 total
739 total
Figure 4.2: NeuAc(α2→3)Gal substrate. The pie charts show the number of siblings
that are found for each residue of each type.
GalNAc(β1→4) transferase absolutely requires the NeuAc(α2→3)Gal substrate. However, path-
way data supports this conclusion, as the GalNAc transferase has its action at two separate points
along the pathway — one which uses sialylated substrate, and the other which uses the simple
Gal substrate residue.
Other sibling
Fuc(!1"4) sibling
Gal(#1"3) sibling
34%
6%
311 total
88%
1%
120 total
Figure 4.3: Gal(β1→3)GlcNAc substrate. The pie charts show the number of siblings
that are found for each residue of each type.
Gal(β1→3)GlcNAc substrate See Figure 4.3. The Gal→ GlcNAc disaccharide primarily occurs
in the absence of siblings (60%), with the remaining 40% found in concert with Fuc(α1→4)GlcNAc
(34%) and NeuAc(α2→6)GlcNAc (6%). The Fuc linkage is found as a sibling of other linkages 90%
of the time, of which the Gal → GlcNAc linkage is a sibling in 99% of cases. Additionally, the
Fuc linkage is a sibling with NeuAc(α2→6) three times — a very small number of cases. The data
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suggests that the Fuc linkage shows a substrate preference for the Gal(β1→3)GlcNAc substrate.
Other sibling
Fuc(!1"3) sibling
Gal(#1"4) sibling
0.1%
14%
2775 total
3%
95%
401 total
Figure 4.4: Gal(β1→4)GlcNAc substrate. The pie charts show the number of siblings
that are found for each residue of each type.
Gal(β1→4)GlcNAc substrate See Figure 4.4. The Gal(β1→4)GlcNAc disaccharide is also pri-
marily a non-branching linkage (86% of cases). Of the 14% of cases where this disaccharide marks
a branch point, the Fuc residue is the primary sibling residue. The Fuc residue is linked on more
than one linkage, but the most predominant is the α1→3 linkage (99%). The Fuc residue is a sib-
ling with other residues 98% of the time, predominantly Gal on a β1→4 linkage (95%). This data
also suggests that the Fuc linkage shows a substrate preference for the Gal(β1→4)GlcNAc linkage.
GalNAc(β1→4)GlcNAc substrate This linkage is found to have no branches in most of the cases
where the structure has been seen, except for a minimal number of Fuc(α1→3)GlcNAc linkages,
suggesting that the GalNAc(β1→4)GlcNAc linkage is a non-preferential substrate for the Fuc⇒
GlcNAc transferase.
Gal(β1→3)GalNAc substrate See Figure 4.5. The GlcNAc(β1→6)GalNAc disaccharide occurs
predominantly in a branching position, with siblings in 92% of observations. Of the siblings, the
Gal residue on a β1→3 linkage is themost prevalent, occurring in 81% of cases. TheGal(β1→3)GalNAc
disaccharide is mixed between having siblings and being a non-branching feature (branching oc-
curring in 46% of structures). For the branching cases, the siblings aremixed betweenNeuAc(α2→6)
(20% of all siblings) and GlcNAc (78% of all siblings) and other residues for the remaining 2%. This
suggests that the GlcNAc is a branching feature on the Gal(β1→3)GalNAc, which can optionally
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Other sibling
Gal(!1"3) sibling
GlcNAc(!1"6) sibling
82%
11%
65 total
36%
10%
149 total
Figure 4.5: Gal(β1→3)GalNAc substrate. The pie charts show the number of siblings
that are found for each residue of each type.
occur when the NeuAc has not capped the structure (the GlcNAc(β1→6)GalNAc disaccharide has
not been observed with any NeuAc siblings).
GlcNAc(β1→?)Man substrate See Figure 4.6. Each of the GlcNAc → Man disaccharides has a
different number of siblings attached to it, depending on the linkage position of the GlcNAc on
Man. The 6-linked disaccharide has a sibling in 96% of occurrences, the 4-linked in 94% and the
2-linked in 40%. The 6-linked is found as a sibling to the 2-linked GlcNAc in 98% of cases where
there is a sibling. The 4-linked is found as a sibling to the Man(α1→3/6) disaccharides, where
it acts as a bisecting GlcNAc linkage in 40% of the sibling cases, and to 2-linked GlcNAc in 77%
of cases. The 2-linked GlcNAc is a sibling of 6-linked GlcNAc in 43% of the observations, and 4-
linked GlcNAc in 55%. There are a very small number of cases (5) where 4- and 6-linked GlcNAc
linkages are siblings to each other, suggesting that the 2-linked linkage is optionally branched by
the 4-linked and 6-linked GlcNAc. The 6-linked GlcNAc exhibits a strong preference towards the
2-linked GlcNAc as a sibling.
GlcNAc(β1→4)GlcNAc substrate See Figure 4.7. The GlcNAc(β1→4)GlcNAc structure is op-
tionally fucosylated on the first GlcNAc, and the sibling data reflects this. The Fuc(α1→6) disac-
charide has a sibling in 99% of observations, which are almost exclusively (98%) GlcNAc residues
on a β1→4 linkage. This disaccharide itself has a sibling in 51% of cases, of which 99% are the
Fuc residue on a α1→6 linkage. This data strongly suggests that the Fuc(α1→6) has an extremely
strong preference for the GlcNAc(β1→4)GlcNAc substrate.
GlcNAc(β1→3)Gal substrate See Figure 4.8. GlcNAc(β1→6)Gal has a sibling in 82% of cases.
Of these, it is sibling with GlcNAc(β1→3) in 98% of observations. GlcNAc(β1→3) has a sibling in
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Other sibling
GlcNAc(!1"4) sibling
GlcNAc(!1"6) sibling
GlcNAc(!1"2) sibling
95%
3%
1%
20%
252 total
73%
416 total
22%
18%
1370 total
Figure 4.6: GlcNAc(β1→?)Man substrate. The pie charts show the number of siblings
that are found for each residue of each type.
only 20% of cases, but of these cases it is sibling with GlcNAc(β1→6) in 89% of observations. This
suggests that the GlcNAc(β1→6) linkage preferentially binds to the GlcNAc(β1→3)Gal site, and
matches with its behaviour as a polylactosamine branching site.
NeuAc(α2→6)Gal and Man(β1→4)GlcNAc substrates Both these linkages occur primarily at
non-branching points, with siblings in 1.7% and 0.1% of cases respectively. The NeuAc linkage is
a capping linkage, whereas the key role that the Man linkage plays in N-glycan synthesis and the
position within the pathway may explain why no other additions are seen at this position.
Man(α1→2)Man substrate This linkage is unique in that it has absolutely no observed siblings,
suggesting that for the Man(α1→2)Man disaccharide, this substrate is only really suited towards
further extension by further Man(α1→2)Man linkages.
A number of disaccharide structural features have been identified through examining the oc-
currences of siblings, and possible substrate preferences have been shown. The action by which
these preferences are realised could be through a compound of enzymes, or through mechanisms
such as substrate competition. It is not possible from the data to draw exact conclusions about
the nature of the reactions catalysing these linkages, but the observations should provide starting
points for further experimental investigation.
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Other sibling
Fuc(!1"6) sibling
GlcNAc(#1"4) sibling
51%
2%
403 total
97%
210 total
Figure 4.7: GlcNAc(β1→4)GlcNAc substrate. The pie charts show the number of
siblings that are found for each residue of each type.
Other sibling
GlcNAc(!1"6) sibling
GlcNAc(!1"3) sibling
81%
18%
2%
812 total
2%
176 total
Figure 4.8: GlcNAc(β1→3)Gal substrate. The pie charts show the number of siblings
that are found for each residue of each type.
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4.3 Pathway verification
Composite structures comprising all the structures found in the pathways can be found in Sec-
tion A.3. Running the analysis against structures from GlycomeDB and GlycoSuiteDB, a number
of coverage comparison maps were obtained for each of the pathways. In order to verify the exis-
tence of the structures, two of the most populated pathways were used to compare the structures
found in GlycoSuiteDB and GlycomeDB (Figure 4.9 and Figure 4.11). As shown in the composite
map, GlycoSuiteDB and GlycomeDB structures have a great deal of structural features in com-
mon. It is important to note that the structural features found in GlycomeDB are a superset of the
structural features found in GlycoSuiteDB. In addition, the number of occurrences of structural
features were compared. There were no significant differences in the distribution of structural fea-
tures — that is, apart from a few branches, there are no large differences between the distribution
of structural topology families between the databases. Since GlycoSuiteDB and GlycomeDB are
independently curated databases, we can draw the conclusion that if a structure is contained in
both databases, it is far more likely to have a valid syntax due to the redundancy in data collection.
45
Fi
gu
re
4.
9:
C
om
pa
ris
on
of
co
m
po
si
te
st
ru
ct
ur
es
fro
m
G
ly
co
S
ui
te
D
B
an
d
G
ly
co
m
eD
B
al
on
g
th
e
N
-li
nk
ed
pa
th
w
ay
.
D
iff
er
en
ce
s
in
fre
qu
en
cy
of
fe
at
ur
es
ar
e
m
ap
pe
d
by
he
at
—
re
d
fe
at
ur
es
be
in
g
m
or
e
co
m
m
on
ly
fo
un
d
in
G
ly
co
m
eD
B.
R
es
id
ue
s
w
ith
ou
ta
ny
he
at
in
fo
rm
at
io
n
ar
e
th
os
e
fo
un
d
in
th
e
pa
th
w
ay
th
at
ar
e
co
m
m
on
to
bo
th
da
ta
ba
se
s.
Th
er
e
ar
e
no
st
ru
ct
ur
al
fe
at
ur
es
un
iq
ue
to
G
ly
co
S
ui
te
D
B.
46
Fi
gu
re
4.
10
:
C
on
tin
ua
tio
n
of
co
m
po
si
te
st
ru
ct
ur
e
co
m
pa
ris
on
fro
m
Fi
gu
re
4.
9
47
Fi
gu
re
4.
11
:
C
om
pa
ris
on
of
co
m
po
si
te
st
ru
ct
ur
es
fro
m
G
ly
co
S
ui
te
D
B
an
d
G
ly
co
m
eD
B
al
on
g
th
e
O
-li
nk
ed
pa
th
w
ay
(c
on
tin
ue
d
on
Fi
gu
re
4.
12
an
d
Fi
gu
re
4.
13
).
D
iff
er
en
ce
s
in
fre
qu
en
cy
of
fe
at
ur
es
ar
e
m
ap
pe
d
by
he
at
—
re
d
fe
at
ur
es
be
in
g
m
or
e
co
m
m
on
ly
fo
un
d
in
G
ly
co
m
eD
B.
R
es
id
ue
s
w
ith
ou
ta
ny
he
at
in
fo
rm
at
io
n
ar
e
th
os
e
fo
un
d
in
th
e
pa
th
w
ay
s
th
at
ar
e
co
m
m
on
to
bo
th
da
ta
ba
se
s.
Th
er
e
ar
e
no
st
ru
ct
ur
al
fe
at
ur
es
un
iq
ue
to
G
ly
co
S
ui
te
D
B.
48
Figure 4.12: Continuation of composite structure comparison from Figure 4.11
In addition, the manual curation process used for GlycoSuiteDB allows for greater confidence
in the correctness of the structures. Even so, structural features still exist that are clearly erroneous
in nature. In order tomaximise the number of structures which can be used, any structural features
which are found only in GlycomeDB were only included if they were found in at least six unique
structures. This threshold was chosen as it was the lowest possible number which still allowed
for manual examination of outlying data points. For each of these composite structural maps,
new structural features were resolved by studying the features, and determining whether they
49
Figure 4.13: Continuation of composite structure comparison from Figure 4.11
represent new pathway data, or can be explained using current knowledge.
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4.3.1 N-linked pathway
The most complex of the composite structures, the composite N-linked pathway, contains 63 new
structural features that cannot be resolved with the collected pathway information (Figure 4.14).
A number of these features can be automatically discarded, since the linkages involved in the
synthesis of the addition were found to be erroneous in the enzyme data collection phase. The
additions to existing pathway information can be broadly classified into two groups: redundant
pathway additions due to deficient pathway data collection, and pathway additions based upon
structural motifs.
Additions due to deficient data collection are similar to those found for addition group A —
describing a mannose disaccharide addition to the tri-mannosyl core N-linked structure. Since
the KEGG data does not specify a specific ordering for the action of the glycosidases at the high
mannose section in the pathway, it is possible that this particular structural feature was not taken
into account. Similarly, the groups marked with HMAN can all be accounted for when manually
referencing the KEGG pathways.
Structural motifs found in extensions are exemplified in addition groups B, C, D and E. Typical
extensions include LacNAc chains, LacDiNAc chains, and the expression of the Sdα epitope. The
Sdα epitopes are generally found only as additions to Gal residues at a level of six residues deep.
LacDiNAc chains seem to occur only on extension of fifth-level GlcNAc.
Interestingly, a GlcNAc(β1→4)Gal disaccharide has been noted as an extension in group E.
Further investigation into the structures that yield this feature show that referencing and database
entry errors have yielded this feature (specifically structures referenced from [81] and [82]).
The Gal(β1→3)Gal extension cannot be found in any more than one reference for human struc-
tures, and so is not sufficiently evidenced to be categorised as a pathway addition.
The remaining Gal, GlcNAc and GalNAc extensions are Type I or Type II chains. The pre-
dominant chains seen are Type II chains, with the Sdα, A, B and O(H) epitopes being found at the
shortest possible Type II chain.
α1→3 fucosylation in general occurs on any of the GlcNAc residues past the tri-mannosyl core.
α1→2 fucosylation occurs on the Gal(β1→4) residues, and in a single case it uses as α1→6 linkage.
Sialylation seems to occur only as an extension to Gal residues. Six-sialylation occurring closer
to the core is generally the rule for the structures deposited into the database. The exception
to this general observation is the 6-linked structure seen in group G. There are only two papers
which provide evidence for this structural feature [81, 83], both found in milk. The data here is
not significant enough to draw any conclusions regarding the general location of these residues.
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Figure 4.17: Continuation of additions along the O-linked pathway from Figure 4.16
55
CD
Figure 4.18: Continuation of additions along the O-linked pathway from Figure 4.16
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4.3.2 O-linked pathway
O-linked glycosylation has been generally thought to be more complex and structurally diverse
thanN-linked glycosylation. Analysis of the pathway extensions onO-linked glycans (Figure 4.16)
reveals the presence of certain patterns regarding the structure of the glycans. In general, exten-
sions on the pathways are made up of Type I/II chain scaffolding, with the exhibition of Sdα, A, B
and O(H) epitopes.
Unlike the N-linked data, there are no additions which are already covered by the existing
pathway. This is due to the more consistent nature of the pathway data obtained from KEGG.
GlcNAc(β1→6) linkages form I-antigen structures. The I-antigen extensions usually form
branch points on the Gal residues. In the observed groups, the residues are only extended by
the Gal(β1→4/3)GlcNAc(β1→6) disaccharide.
Extensions in group A are primarily Type I/II chain extensions. Although the Type I chains
are less repeated than the Type II chains, there is no evidence to suggest that any Type I chains
could not be repeated further. Group B consists of Type I/II chains, an I-antigen structure and
Sdα epitope. Group C can be constructed through a Type I/II chain framework, capped with A-
antigen epitopes. Group D shows the beginning of a Type I chain capped with an A antigen. Any
I-antigenic structures tend to yield shorter chains than regular Type I/II chains.
Fucosylation occurs upon the GlcNAc and Gal residues. Fucosylation on the GlcNAc residues
occurs on 3- and 4-linkages upon Type I/II chains. Evidence for both types of fucosylation poten-
tially occurring is limited in group B. Similarly, the pattern for fucosylation on GlcNAc is difficult
to determine, due to the limited amount of evidence on these structural features. Fucosylation on
Gal residues only occurs via an α1→2 linkage.
Sialylation occurs only on the Gal and GalNAc residues on 3- and 6-linkages. GalNAc sialyla-
tion only occurs on the reducing end GalNAc on a 6-linkage, as per the original pathway. Deter-
mining a pattern for the sialylation of Gal residues is not possible, as no obvious schemes for sia-
lylation are evident. The absolute number of structures in which these features have been found is
also low, so any conclusions drawnmay be spurious. In addition, NeuAc residues are further sub-
stituted by NeuAc residues in two cases — both times on 6-linkages. The NeuAc(α2→6)GlcNAc
residue has been determined to be a data entry error [84].
4.3.3 Glycosphingolipid biosynthesis
Additions along this pathway are fucosylations and Type I/II chain extensions. For the neo-
lactoseries pathway (Figure 4.19), additions are predominantly for the A-antigen along the neo-
lactose chain. Additionally, a fourth lactose unit is added to the chain. The Gal(β1→3)GlcNAc
linkage forms part of a hybrid Type I/II chain.
Along the lactoseries pathway (Figure 4.20), the additions in group A are common to those
found in the neo-lactoseries extension. Within group B, the extensions can be classified into Type
57
AB
GGTA1/ABO
LAcNAc
GGTA1/ABO
Figure 4.19: Neo-lactoseries glycosphingolipid extensions. Extensions are marked in
red, and are explained in the text for larger extensions, while smaller extensions are
labelled as per the extensions key (Table 4.6)
I and II chains. The Type II chains are regular repeating units, but the repeating Type I chain has
been associated with carcinoma [85] [86] and has been shown on the Le(c) antigen.
4.3.4 Structures outside pathways
Structures that do not belong to any particular pathway also have features which need to be re-
solved. In order to identify the parts of the composite structure that are most important to study, a
similar compositing of structures was undertaken, resulting in maps rooted at Gal, Fuc, GalNAc,
Glc, GlcNAc and Man. Many of these structures exhibit characteristics of being sub-structures of
larger structures, as they have the same structural features as their counterparts within pathways.
Gal-rooted structures (Figure 4.21) are all Type I/II chains as well as I-antigenic structures.
Fucosylation and sialylation patterns are also similar on these structures, with fucosylation occur-
ring only on the 3- and 4-linkage positions on the GlcNAc, the 2-linkage position on the galactose,
and sialylation only on the 3-linkage position on the Gal residue. The Gal(β1→4)Gal linkage is
not a well evidenced structural feature, and is an artefact due to an error in the database curation
process [87].
Fuc-rooted structures (Figure 4.22) are not described in pathways, but the structures are known
O-linked fucosylation structures. Possible enzymes for the synthesis of each of the linkages are
marked out on the figure. It is important to note that the terminal NeuAc(α2→6)Gal linkage is the
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AB
Figure 4.20: Lactoseries glycosphingolipid extensions. Extensions are marked in
red, and are explained in the text for larger extensions, while smaller extensions are
labelled as per the extensions key (Table 4.6).
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B Antigen
Type I
Type I
Type II
Type II
Figure 4.21: Additions to Gal-rooted sugars. Gal and GlcNAc extensions are labelled,
while the Fuc and NeuAc extensions have not been individually labelled. Structural
features that have been examined and found to be erroneous have been presented
desaturated.
Figure 4.22: Additions to Fuc-rooted sugars. The Gal(β1→3)Fuc linkage has been
examined and found not to be a valid new structural feature.
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correct linkage position for this residue, as several reviews [88] [89] incorrectly list the linkage as
a α2→3 linkage.
GalNAc-rooted structures are actually three sets of disaccharides: GalNAc(α1→3)GalNAc,
GlcA(β1→3)GalNAc and Thr(α1→3)GalNAc. The first two can be resolved to fragments of the
glycosphingolipid globoseries and chondroitin sulfate biosynthesis pathwayswith the genes GBGT1
and CHSY1 respectively. No enzyme exists in the database for the synthesis of the final disaccha-
ride and it does not form part of any pathway described here.
Glc-rooted structures have a number of features. The Gal(β1→3)Glc linkage, as shown in
the disaccharide analysis, may be an artefact. Structures such as fucosylated and di-fucosylated
lactose are also observed. Most structural features are centred around modifications on a lactose
core.
GlcNAc-rooted structures exhibit many similarities to the N-linked pathway, and most of the
structural features can be traced back to the N-linked pathway. Exceptions are possible extensions
upon LacNAc structures, with di-sialylation (NeuAc(α2→8)NeuAc(α2→3)Gal(β1→4)GlcNAc), and
the B-antigen being found. The GlcA(β1→3)GlcNAc(β1→4)GlcA(β1→3)GlcNAc structure is
hyaluronan, which is also found in a longer chain for the GlcA-rooted structure.
Man-rooted structures are all components of the N-linked pathway and do not require any
further explanation.
4.3.5 Structures analysed
In total, 3348 human structures were analysed. This number does not include structurally am-
biguous sequences, which were removed from the analysis due to their lack of credibility. Of the
structures analysed, 57 repeating structures were not included in the automatic process, as it is
more efficient to analyse them manually, rather than to introduce complexity into the program
code.
Sulfates, phosphates and methylation were all removed from the remaining structures, as they
can be considered secondary modifications to the foundation residues and sequences. In addition,
25 residue names were masked with a generic residue name, as the residue names could not be
easily mapped onto the analysis model. The residue names were associated with various synthetic
chemical modifications, andwere deemed to have been synthesised apart from the regular biosyn-
thetic pathway. As none of these residues were numerous enough to appear in the disaccharide
table, it was safe to make this simplification.
Only 322 of the resulting structures fully matched the KEGG pathway data (Table 4.3). Given
that there are 122 unique structures as end products in the pathways, it is clear that some structures
have been duplicated due to stripping features such as sulfation and phosphates. None of the end
products in the chondroitin sulfate biosynthesis pathway were found in the database. The 322
structures represent only 9.6% of all the structures in the database, which is a clear indicator of the
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degree of structural elaboration that occurs. In total, 844 structures did not match with a pathway,
and the root residues of these structures are listed in Table 4.5.
Of the 2125 structures that partially matched with structures (pathway distribution shown in
Table 4.4), the majority of structural additions could be found along the N- and O-linked path-
ways. This reflects the interest shown in the different classes of structure, and the attention de-
voted in literature.
Pathway Number matched Number in pathway
N-Linked 153 31
Neo-Lactoseries GSL 56 34
O-Linked 40 10
Ganglioseries GSL 28 20
Lactoseries GSL 27 10
Globoseries GSL 12 7
Chondroitin sulfate 4 6
Lacto and Neo-lacto series common GSL 2 3
Table 4.3: Count of fully matched structures per pathway.
Pathway Number matched
N-Linked 1266
O-Linked 621
Neo-Lactoseries GSL 112
Lactoseries GSL 80
Ganglioseries GSL 22
Globoseries GSL 10
Lacto and Neo-lacto series common GSL 7
Chondroitin sulfate 7
Table 4.4: Count of partially matched structures per pathway.
4.3.6 Repeating structures
Repeating structures were examined separately. From a manual examination of the structures,
repeating structures were identified as chondroitin, dermatan sulfate or chondroitin sulfate B, and
as heparan sulfate structures. In addition, a poly-sialic structure was seen as found on NCAM
[90]. A number of LacNAc(b1-6) repeating structures were seen, but after examining the literature,
there were fewer than six unique structures which supported this structural feature, and so this
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Root residue Number of structures
Glc 109
Xyl 10
GalNAc 43
Gal 120
Fuc 4
GlcA 10
NeuAc 3
Man 47
GlcNAc 473
Other 25
Table 4.5: Root residues of unmatched structures.
Structural feature Description
LDN LacDiNAc structure
HMAN High mannose structure
SLDN Sialylated LacDiNAc structure
SDA Sdα epitope
B antigen Part of Gal(α1→3)[Fuc(α1→2)]Gal epitope
A antigen Part of GalNAc(α1→3)[Fuc(α1→2)]Gal epitope
BGNAC Bisecting GlcNAc
Table 4.6: Extensions labelled in Figures 4.14, 4.16,4.19 and 4.20.
was deemed to be in error.
4.3.7 Summary of additions
Extensions on structures can be considered to exist upon the GlcNAc residues. There are a number
of distinct extensions which can be applied to these residues.
Type I/II chain extensions In general, extensions upon GlcNAc are based upon an extension
using a Type I/II chain, with branching occurring when a 6-linked GlcNAc is attached. Lists of
the chains and the frequency of occurrence are listed in Tables 4.7, 4.8 and 4.9. I-antigen branching
is only present in O-glycans, with the branching occurring mainly at the mannose core in N-
glycans (with the exception of nine structures on N-glycans). Type I chains have been found as
shorter repeating units (contradicting results from literature [91]), while the Type II chains can
(theoretically) be indefinitely repeated. Chains of repeating Type II/6-linked GlcNAc features
63
Chain components Count
II 3087
II,3,II 148
I 42
II,3,II,3,II 29
II,6,II 6
II,3,I 6
I,3,II 3
II,3 2
II,3,II,3,II,3,II 2
II,6 2
3,I 1
I,3,I 1
I,6,II 1
Table 4.7: Gal-GlcNAc chains found on N-linked structures. I/II corresponds to a Type
I/II chain unit, while 3/6 corresponds to a 3-linked and 6-linked GlcNAc.
have been reported [92], although they have seldom been found in the databases.
Mixed Type I/II chains are present — but for mixed chains, the Type I units occur only at the
start or the end of the chain. Similarly, 6-linked GlcNAc chain components can be mixed with the
3-linked GlcNAc, but only at the start or the end of a chain.
LacDiNAc structures A structural feature proximal to terminal extensions, the LacDiNAc struc-
ture (GalNAc(β1→4)GlcNAc) is not extended, but is found upon N-glycans on GlcNAc residues
directly attached to the mannose core.
Fucosylation Gal residues exhibit only α1→2 fucosylation, while GlcNAc residues can be ex-
tended by 3- and 4-linked Fuc residues. Gal fucosylation occurs as part of a terminal epitope
structure. The substrate analysis suggests that any GlcNAc fucosylation occurs after the Gal
residue has been attached, and occurs in a linkage complementary to the chain; Type I chains
receive α1→4 linked Fuc residues, while Type II chains receive α1→3 linked Fuc residues. This
fucosylation pattern is common to all pathways.
Sialylation NeuAc residues can be used to terminate a Type I/II chain on an α2→3 or α2→6
linkage upon Gal residues. Since Gal residues are extended by GlcNAc residues on 3-substituted
linkages, the 3-linked NeuAc is always a terminal extension. Substrate analysis of the 6-linked
NeuAc indicates that the residue is found primarily as a terminal residue. The current data set
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Chain components Count
II 321
I 58
II,3,II 53
3,II 51
3 51
II,3,I 50
3,I 32
6,II 23
II,6,II 20
6 11
II,3,II,3,II 9
II,3 8
3,II,3,II 8
II,6 7
3,II,6,II 7
II,6,I 5
II,3,II,3,I 4
3,I,3,I 4
3,II,6 4
3,II,3 3
I,3 2
3,II,6,I 2
II,6,II,6,II,6 2
II,6,II,6 2
I,6,I 1
II,3,II,3,II,3,II 1
II,3,II,3,II,3,II,3,II 1
3,II,3,II,3,II,3,II 1
II,6,II,6,II,6,II,6 1
I,3,I 1
3,II,3,II,3,II,3,II,3,II 1
3,II,3,I 1
Table 4.8: Gal-GlcNAc chains found on O-linked structures. I/II corresponds to a Type
I/II chain unit, while 3/6 corresponds to a 3-linked and 6-linked GlcNAc.
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Chain components Count
3,I 98
3,II 84
3,II,3,II 46
6,II 45
II 33
3,II,3,II,3,II 22
3,II,6,II 19
3,II,3,I 14
6,II,3,I 13
3 10
3,I,3,I 7
6,II,3,II 6
I 6
3,II,3,II,3,II,3,II 5
3,I,3,II 5
3,II,3,II,6,II 4
3,II,3 3
II,6,II 2
II,3,II 2
6,II,6,II 1
3,II,3,II,3,I 1
6 1
3,II,3,II,3 1
6,II,3 1
II,3 1
3,I,6,II 1
6,I 1
Table 4.9: Gal-GlcNAc chains found on Glc-rooted structures. I/II corresponds to a
Type I/II chain unit, while 3/6 corresponds to a 3-linked and 6-linked GlcNAc.
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seems to suggest that this linkage also is a terminal feature on chains, and not a mid-chain modi-
fication.
Epitopes In addition to regular NeuAc terminal residues, there are three chain terminating epi-
topes which can be found: Sdα, A-antigen and the B-antigen. The Sdα epitope requires the pres-
ence of a NeuAc(α2→3)Gal substrate, while the A and B antigen are associated with the presence
of the Fuc(α1→2)Gal substrate.
4.4 Structural validation
The pathway data has been verified to be a surrogate for evaluating sequences with respect to
context. The implementation of the validation technique is a specialisation on the generalised al-
gorithm for validating structures against pathway data (Figure 3.3). Any extensions on the struc-
ture to be validated will be compared against chain extensions, such that the chain must match
the chain patterns listed above. Any structure that does not match these chain extensions will be
deemed invalid.
I have implemented the algorithm in software as a web application. Figures 4.23, 4.24, 4.25
and 4.26 are screen-shots from the application. The validation tool is split into two components
— the builder tool and the validator. The builder tool allows for the rapid and easy encoding of
structures using a drag and drop methodology. The composed structure can then be sent to the
validator tool that marks up the structure with annotation according to the rules elucidated in this
thesis.
Both the builder and validator have been designed as modular components such that their
functionality can be included in other applications. Using API encodings such as REpresentational
State Transfer (REST), it is possible to call the application and retrieve the results as SVG or other
image files.
Testing the performance of the validator, the software implementation was used to determine
the number of structures fully covered by the algorithm from both the GlycomeDB and GlycoSuit-
eDB data sets. For GlycomeDB, 70 out of 472 unique structures (14.8%) were listed as containing
errors. GlycoSuiteDB listed 27 out of 288 unique structures (9.3%). The structures chosen to vali-
date both the databases were human structures stripped of any sulfation or phosphorylation, and
any uncertain or fuzzy structures were discarded. This validation suggests that there are fewer
errors in GlycoSuiteDB— a result consistent with the curation procedures that were put into place
to maintain quality. It is not possible (without manually examining the data sets) to determine the
false negative rate for the validation algorithm.
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Figure 4.23: Screenshot of the sugar builder tool used to encode structures to be
validated. Structures are incrementally built up using a drag and drop method.
4.5 Glycome estimation
When calculating the size of the glycome, we need to first estimate the size of chain extensions that
are applied to the basic pathway structures. After estimating the size of chains, we can calculate
the combinations of attachment points that the chains can be attached to, and have an estimate of
the size of the human glycome.
4.5.1 Chain lengths
Enumeration of chain combinations for N-linked structures.
f(n) = II + n3II
+ (n− 1)3II
f(2) also has these chains:
II + 6II
I + 3I
+ 6II
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Figure 4.24: Anomer selection when building structures using the builder tool. A
residue is selected from the donor palette and dropped onto the substrate residue. The
anomer selector menu appears to allow the user to select the anomeric configuration.
+ 3II
Enumeration of chain combinations for O-linked structures is complicated by branching oc-
curring along the chains. Since the branching for O-linked structures occurs primarily along the
chain elaboration, the calculation of the number of chains is slightly modified. Branching occurs
primarily at the start of the chain, and is not extended beyond a single unit.
f(m,n) = I + [m6I] + (n− 1)3I (m = 0..1, n = 2)
+ [m6II] + (n− 1)3I (m = 0..1, n = 2)
II + [m6I] + (n− 1)3II (m = 0..1)
+ [m6II] + (n− 1)3II (m = 0..1)
+ [m6I] + (n− 2)3II + 3I (m = 0..1)
+ [m6II] + (n− 2)3II + 3I (m = 0..1)
+ (n− 1)6II
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Figure 4.25: Linkage selection when building structures using the builder tool. After
the anomer is selected, the linkage menu appears, allowing the user to select the
desired substitution position on the substrate residue.
Enumeration of chain combinations for GSL structures.
n3II
6I+ (n− 1)3II
3I+ (n− 1)3II
n6II
6II3II
3I
3I3I
Based upon the enumerations of chain types, a generalised formula for the number of combi-
nations of chains can be derived. Since there are optional fucosylation events for each one of the
chain types (out of 3I, 3II, 6I and 6II), there are 2n different combinations of chain components —
due largely to the number of ways in which the fucosylation can occur. O-linked chains are more
complicated as the branching can occur along the chain itself. Generalising this to the different
chain types:
N-linked chains size(n) = 2n + 2n−1 + 1 + 3 = 3(2n−1) (+4when n = 2)
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Figure 4.26: A structure that has had the validation algorithm run on it. This struc-
ture is not a valid structure - as indicated by the residues marked with a red highlight.
Chain extensions are marked with a green background, valid terminal decorations are
marked with a blue background, and invalid components are marked with red back-
grounds. For invalid components, the linkages are drawn in red or blue, corresponding
to no known enzymes and known enzymes encoding the linkage.
O-linked chains size(n) = 4when n = 1, 15× 2n when n = 2, 10× 2n otherwise
GSL chains size(n) = 2n + 2n−1 + 2n−1 + 2n + 3 = 6(2n−1) (+2when n = 2,+1when n = 1)
4.5.2 Extension sizes
Since the size of structures is limited, it is reasonable to examine the maximum dimensions of each
of the extensions on each of the pathways. For each structure from the database, the extensions
were collected, and statistics were collected on the number of extensions, as well as the number of
residues and degree of branching within the extension (Table 4.10). The numbers listed cover 90%
of the extensions observed. From the size of the extension, the maximum possible chain size that
can fit into the number of residues is calculated.
4.5.3 Multiple chains
Since multiple chains can extend a structure, it is possible to calculate the total number of com-
binations of multiple chain lengths. For example, for two chain extensions on a single N-linked
structure of length 1, there are a total of (3(21−1))2 = 32 = 9 combinations. Two one-unit length
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% Total Extensions Size Chain size Branches
N
li
nk
ed
18 1 4 2 2
34 2 3 1 1
24 3 3 1 1
24 4 3 1 1
(of 2527)
O
li
nk
ed
29 1 6 3 2
46 2 4 2 1
24 3 3 1 1
1 4 3 1 1
(of 1045)
G
SL
51 1 6 3 2
40 2 4 2 2
9 3 2 1 1
(of 275)
Table 4.10: Maximum sizes and branch counts to cover 90% of extensions for the
given pathways. Extensions sizes are given in number of residues.
chains can be denoted as 1, 1. Extending this to the observed combinations of chain extensions,
the total number of combinations for chain extensions can be calculated (Table 4.11). Not all com-
binations of chain length are listed, as not all combinations were observed in the data.
Multiple chain Combinations
1, 1 9
1, 2 21
2, 2 49
1, 1, 1 27
1, 1, 2 63
2, 2, 2 343
1, 1, 1, 1 81
Table 4.11: Total numbers of theoretical chain extensions for N-linked structures.
4.5.4 Attachment points
To calculate the attachment points, the number of structures along the pathways that had exten-
sion points was counted. For example, 16 distinct extension points were counted for a single chain
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extension. For multiple chains, the ordering of the selection of attachment points is important, and
so permutations (Pnr ) of attachment points are calculated. Examining the N-linked pathway ele-
ments, it is seen that for 2-chains, there are 3P 22+P 32+2P 42 = 36 permutations of attachment points.
For 3-chains there are P 33 + 2P 43 = 15 attachment points, and 2P 44 = 48 points for 4-chains. There
are seven 1-chain attachment points along the O-linked pathway, and only a total of four (two
P 22 points) two-chain attachment attachment points. The higher number of extensions in compar-
ison to extension points seen in Table 4.10 can be attributed to decorations such as fucosylation
occurring on points along the existing structures.
4.5.5 Final calculation with elaborations
To calculate the final size, the terminal elaborations need to be applied to the chains. Examining
the database, the A and B antigenic decorations are uniform— that is they are not found together
in structures. As such, it is possible to consider there to be four types of modification A/B, Sdα,
3-linked NeuAc and 6-linked NeuAc. This assumption is further extended to all elaborations such
that all chain elaborations are the same if present. In addition, there is a null modification, where
there is no further elaboration to the chain. This means for each chain there are five possible
extensions, which is multiplied by two for each further chain. Combining the attachment points
and sizes of chains:
total = (1− chain positions)× (1− chain combinations)× 5
+ (2− chain positions)× (2− chain combinations)× 5× 2
+ (3− chain positions)× (3− chain combinations)× 5× 2× 2
+ (4− chain positions)× (4− chain combinations)× 5× 2× 2× 2
For N-linked structures, this is:
total = 16× 10× 5 + 36× 79× 10 + 15× 433× 20 + 8× 81× 40
= 800 + 28440 + 129900 + 25920
= 185060
For O-linked structures, this is:
total = 7× 72× 5 + 4× 3856× 10
= 2520 + 154240
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= 156760
In total, for N and O-linked structures, this yields a total potential glycome size of 341,820
distinct sequences. This is an approximation, as features such as degree of fucosylation and sia-
lylation were not fully characterised and the branch length has been limited to cover the top 90%
of most commonly occurring structural features. The estimate suggests that the total number of
glycan sequence— at least in the human glycome—will be in the order of hundreds of thousands
of structures.
4.6 Summary
Analysis of both individual enzyme data and pathway data suggests that the repertoire of glycan
structures can be accounted for using a combination of pathway data and extensions. Generally,
structures seem to be built up on a core framework, which is then decorated by various epitope,
fucosylation and sialylation events. This observation confirms general knowledge about the syn-
thesis of glycans. Although further modifications like sulfation and phosphorylation have not
been accounted for here, the diversity of glycan structures appears to be restricted based upon
observed structures. A description of the final algorithm for validating structures can be found in
Section 4.4.
A total of 11 catalysed linkages were found in the database that did not have any enzyme
information associated with them. Furthermore, three linkages catalysed by reactions associated
with genes did not have any structures to support the existence of these linkages. See Table 4.1 for
the list of linkages.
Substrate and neighbour analysis of the structures (Section 4.2) yielded no significant stan-
dalone insights into structure. While the neighbouring monosaccharide on a substrate did seem
to correlate with known preferences and the order of application of transferases, further wet lab
investigation is required to determine whether the suggested order of application of enzymes oc-
curs in nature.
The validation algorithm was realised as a web application, and then used to determine the
validity of the structures from both GlycomeDB and GlycoSuiteDB. While no conclusions can be
drawn about the effectiveness or accuracy of the algorithm in detecting errors in the database,
the analysis does provide some information as to the relative validity of GlycoSuiteDB over Gly-
comeDB.
An estimation of the size of the glycome yields approximately 350,000 distinct structures.
While the calculation of the number of structures does not cover every single structural class,
it does cover the classes most susceptible to exponential factors, and is a good approximation of
an upper limit.
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Chapter 5
≈
Database networking
A
LGORITHMS FOR VALIDATING STRUCTURES were created as part of the EUROCarbDB
project — a European effort to create a comprehensive database of experimentally sup-
ported glycan structures. The database uses an open-curation model to guide its data
collection, and as such requires sophisticated automatic validation procedures to maintain qual-
ity.
One of the core goals of EUROCarbDB is to decentralise the database. This essentially means
that the database acts as a distributed application, storing data locally to installations. The dis-
tribution of the database makes it less vulnerable to funding issues that are common with many
databases. To enable this kind of infrastructure, a network layer that allows for the distribution of
queries and raw data files was established during this thesis.
5.1 Application architecture
The EUROCarbDB application is designed as a web-based application, using a standard three-tier
design with an added networking component. Standard architectural choices were made for the
application to ease the development process, and to ensure that any changes to major components
of the architecture would not have a significant impact on development.
The system can be generally categorised as comprising four key components — users, soft-
ware, databases and the network. Figure 5.1 illustrates the relationships between the different
components. The user interacts with the software either through an HTML interface, program-
matically via the web services, or through a Java [93] application. Web services are offered using
the SOAP protocol. Although the first prototype is a web-based application, the design has been
chosen to accommodate the use of desktop applications as potential methods to deliver software.
The software component interacts with the Tranche [94] network, experimental data and the back-
ing database. Inter-node communication occurs via Tranche or through the web services interface.
The system architecture is a variation on the three tier-design for web-based systems. The three-
tier system encourages Model View Controller (MVC) design pattern usage, making the source
code more maintainable and manageable. The MVC pattern can be mapped onto this design,
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Figure 5.1: The overall architecture of two EUROCarbDB nodes communicating with
each other. In the most simplistic representation, the system comprises software and
database components. Interactions between nodes occur via SOAP or through the
Tranche network cloud intermediary. Experimental data associated with records on
each node can be transferred via the Tranche network.
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Figure 5.2: The overall network architecture of the system. Each source and sink
is a node within the network, and the arrows represent interactions between nodes.
Sources conceptually act as providers of information to the network, whereas sinks
consume information on the network.
whereby the model is represented by the Object Relational Mapping (ORM) and database compo-
nents, the view layer by the HTML and web services components, and the controller layer by the
actions component.
5.2 Design
5.2.1 General network layout
To achieve the goal of distributing the operation of the database, a network layer is necessary. The
goal of the network layer is to distribute the functions of the application transparently without
user knowledge. The network is arranged as a set of nodes, with both pre-defined and ad hoc
connections between nodes. Communication between nodes occurs on the query and data layers.
Nodes Each site participating in EUROCarbDB has at least one node on the network. Each node
can have different levels of functionality, depending on the capabilities that the host institution
wishes to expose. As shown in Figure 5.2, depending on the network layer in which the node
participates, the node can be labelled as a data source, data sink or both. Source nodes provide
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data to the network via the data layer, whereas sink nodes provide query facilities over the query
layer.
Node layout The network is laid out in an undirected mesh layout, with each node able to make
connections directly with other nodes as required. The network is initially closed — with each
node being aware of the other nodes a priori— but eventually expands to accept other nodes onto
the network in a dynamic fashion.
The design of the network is split into two basic layers:
Query layer This layer allows queries and control signals to be distributed to the component
nodes in the network and then handles the collation of results. The query layer has been designed
for most ease when traversing firewalls and returns results in well-defined XML formats.
Data layer This layer allows the database to send raw data between nodes in the form of core
database updates, or to distribute experimental data between nodes. The design of this layer is
optimised for transferring large blocks of data at irregular intervals.
5.2.2 Query layer
The query layer is critical to allowing EUROCarbDB to function in a distributed manner. As
well as allowing for distributed queries, this layer has several functions involving administration
and signalling between nodes on the network. In general, the query layer provides a wrapper
around the execution model of the application, exposing the actions as services. The query layer
provides facilities to ensure the database can function without a central node, distributing queries
to appropriate nodes in cases where the node itself cannot fulfil a query.
The use of a distributed query layer is needed when dealing with large data sets. Although
facilities to transfer large data files from one node to the other are available, it is often faster to
perform the query where the data is located. By distributing the query to the node closest to the
data, the results can be returned more quickly as there is no additional data transfer required.
5.2.3 Data layer
The data layer is concerned with the distribution of primary data amongst nodes in the network
— including the distribution of core data along the network and the distribution of experimental
data amongst nodes.
The distribution of core data on the network is crucial to maintaining the integrity of the
database across all the peers. Rather than requiring full availability of nodes to all other nodes
on the network to maintain uniqueness through a query system, a synchronisation process has
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been designed to maintain copies of the core data across all nodes. Since an implementation of
this synchronisation process has not been completed, details can be found in the 2007 annual re-
port from the EUROCarbDB project [95].
5.3 Software results
The establishment of prototypes of the query and data layers is the key result of the EUROCarbDB
developments. On the query layer, two prototypes were developed — a first implementation of
database-to-database querying was established with the BCSDB [96] to investigate the difficulties
that may arise when performing distributed queries. The main implementation resulted in the
ability to distribute the action of arbitrary queries. This abstraction of queries is possible due to
the design chosen. The data layer allowed for the upload and download of arbitrary files from
the Tranche network. Although these two main achievements allow for some distribution of the
application, further sophistication is required before it becomes fully decentralised.
5.3.1 Glycosciences.de to BCSDB connection
To test various protocols for connecting databases, the ability to send queries to other databases
was tested on a connection between the Glycosciences.de database and the BCSDB [96]. The con-
nection between the two databases was implemented as an add-on SOAP module within the ex-
isting PHP and Perl database applications. Although it was relatively simple to establish the API
for remote procedure calls, complications arose from resolving the different data types that were
stored in the database. Because different vocabularies are used, it became necessary to normalise
them. Each query was forwarded from the spawning application synchronously— the source had
to wait for the target to finish running its query before it could return results. This serialisation of
queries has performance implications — but given the relatively low usage of the database, it is
not practical to optimise the solution through asynchronous job dispatch.
5.3.2 Query layer implementation
The query layer implemented for EUROCarbDB acts as an adaptor on top of the action con-
trollers. Through configuration of the application, it is possible to forward action requests to
remote servers. This allows for remote dispatch of jobs. Results are returned from the remote
actions, and then collated on the originating server. The interface is implemented using SOAP,
serialising both query and results out to XML.
Actions are only required to be stateless to take advantage of this capability. Only input and
output data fields are modelled in the SOAP messages, so any session or state information for a
particular action is not saved. The execution of each action is like a single atomic unit of work,
where all the relevant data can be encapsulated in the input message and output result. The
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system was tested using some simple actions, and was further used to facilitate a connection
between a remote application (Glycoworkbench) and the server application.
No stress testing of the application was undertaken. Since there is neither a significant amount
of data in the database, nor a sufficient number of nodes to test scalability, it is difficult to test the
performance of the system under heavy load. In regular usage, the system itself will only see light
usage, so in many respects the performance of the system under stress conditions is not important.
5.3.3 Data layer implementation
The data synchronisation layer has not been fully implemented in EUROCarbDB. To achieve some
degree of data synchronisation, the Tranche system has been integrated into the application.
To integrate Tranche into EUROCarbDB, the separate upload, download and daemon software
modules were integrated into the web application framework. Configuration data common to
the modules was integrated into the core application configuration, and the daemon process tied
into server startup and shutdown. Users are converted into Tranche users from application users
automatically, with the user identities signed with the appropriate certificate.
The basics of data synchronisation have been added to the application – data can be serialised
and deserialised, but no record merging is in place to handle updates of records.
5.4 Implementation details
The application is implemented as a first prototype using a three-tier application environment
— operating on the Java [93] platform, using the Hibernate [97], Struts 2 [98], Tomcat [99] and
PostgreSQL [100] libraries to add the desired functionality to the basic server. In addition, JiBX
[101] as well as XFire [102] are used to supply the XML functionality. In general, open-source
libraries and applications are used as the basis for the entire application. An overview of the
general software application architecture can be seen in Figure 5.3.
Java and Tomcat
The Java language is a bytecode-compiled language, known for the ease of cross-platform de-
velopment and wide availability of libraries. The Apache Tomcat application server provides an
environment under which Java web-based applications can be offered to the public. Both the Tom-
cat server and Java are open source, albeit licensed under different schemes (Apache 2.0 License
and GNU Public License (GPL) v2 respectively).
Hibernate
Hibernate provides an ORM layer onto the database by reverse engineering a set of Java source-
code files from the database schema. By reverse engineering the Java API from the database
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Figure 5.3: Relationships between the software components in EUROCarbDB. This
diagram illustrates the software modules for the various architectural features shown in
Figure 5.1. The architecture is a Java [93] and SQL database-based system, in which
the Struts and Hibernate components form significant reused parts in the architecture.
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schema, there is no need to synchronise the changes between system models, the database model
and object model. As the reverse engineering process is a somewhat naive process, the reverse en-
gineered source code needs to be modified so that an appropriate API is exposed for manipulating
the objects.
PostgreSQL
PostgreSQL is used as the database component in the application. The optimal way to store data
for the application is in a relational database, and the PostgreSQL database provides the best set
of features and performance of the open source databases. Connection to the ORM component,
and the Java applications in general is achieved through the use of JDBC libraries.
Struts 2
Web requests are essentially stateless operations. Each request does not know about the requests
which have occurred before it, and there is nothing within HyperText Transfer Protocol (HTTP)
to explicitly bind a series of requests together in a transaction. For this reason, support for saving
state has to be added to the server or client side. Server-side state is established by using cookies
— identifiers stored on client machines — which can tie a particular request to a particular server
state. Many changes to state can occur for a request, such as a user logging in, or being part-way
through a multi-stage action. Because much of this functionality is common to many web appli-
cations, a number of frameworks have been developed to provide these common functions. One
such framework is Struts. Struts follows an MVC approach to the development of web applica-
tions, providing a set of Java classes which provide the basic functionality within the application.
Core to the function of Struts is the concept of an action. Source code associated with an action
is related to a single unit of work, or a verb, which is applied to the system. Simple actions can be
‘Add biological context’, ‘Associate taxonomy’, or ‘Upload experimental data’. Each action should
be atomic, and should not be dependent on the state of other actions. Struts manages the execution
of the actions, as well as executing a series of pre- and post-execution methods as interceptors.
XML libraries
JiBX and XFire together provide support for SOAP within EUROCarbDB. In order to avoid dupli-
cating work, JiBX was used as the binding library for both SOAP and generic XML marshalling
and unmarshalling. JiBX functions as a bytecode manipulation of classes, marking out the bind-
ing of fields in an object to elements in an XML file. The XFire library is an implementation of
the SOAP protocol, and handles the dispatch of SOAP messages to appropriate methods. A spe-
cialised SOAP message to Struts’ action wrapper was written to allow the use of all actions as
SOAP methods.
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5.5 Conclusions and future directions
The development of a comprehensive database for glycomics is of great importance to the contin-
ued development of the field. While the collection of data can help in the short term, the long-term
benefits through data mining are even more attractive. The EUROCarbDB project, of which this
thesis is a part, aims to meet the needs of the glycomics community. To meet the goals of distri-
bution, accessibility, longevity and quality, a network component was developed as part of the
project to lend decentralised qualities to the software. The network component was developed
in two parts: the establishment of a query layer, and the integration of the Tranche system to
distribute large files.
The creation of a query layer was undertaken to allow the distribution of queries between
nodes on the network. As it may not be expedient to transfer the raw data from node to node
when ad hoc queries are performed, the application needs ways to send queries to other nodes and
collate results. A SOAP-based API was used to interface the controller logic of the application,
acting as a proxy to remote execution of the controller. The system was tested using stateless
actions, as the nature of the proxying did not lend itself to stateful remote execution.
Although the data layer was fully designed, its full implementation was not completely estab-
lished for the thesis. The Tranche system was integrated into the project to allow for large data
sets to be easily transported from node to node. The integration featured both user and daemon
integration.
Future development of the network layer will involve the implementation of database syn-
chronisation. Because the network has been tested neither under load nor in a scaled-up network
topology, the performance of the system under these stress conditions will need to be evaluated
and optimised.
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Chapter 6
≈
Conclusions
M
AINTENANCE OF DISTRIBUTED DATABASES is a challenge due to the decentralised na-
ture of the data. To ease the burden, tools can be designed to automatically check the
data for both syntax and context validity. Whereas syntax-checking algorithms can be
independently applied to incoming data, context-checking algorithms are necessarily dependent
on examination of other entries within the same context.
Validation of structures and sequences should be done at the time of data deposition to provide
the most timely feedback to the depositor. To implement this kind of checking on a distributed
database requires the examination of the full data set. In practical terms, this means that the
deposited sequence should be compared against the complete glycome to examine whether the
sequence contains any new structural features that need to be further verified. Because no com-
plete databases of glycomes exist, a complete contextual examination via one-to-one sequence
comparison is impossible. Instead, biosynthetic information can be used to provide contextual
data against which structures are verified.
Since all glycan structures follow a biosynthetic pathway that guides synthesis, all sequences
within a context must conform to the rules of synthesis. The degree to which a structure conforms
to the biosynthetic rules can be determined by a simple test which acts as a surrogate to test the
appropriateness of the sequence to the full context. Any structural features that are not controlled
by a biosynthetic pathway are either errors or represent new biosynthetic knowledge.
Before verifying new sequences, the pathway data was validated to ensure the quality of the
reference data. To achieve this, pathway data was compared with existing sequence databases to
clearly identify potential paths for elaboration of structure.
In the process of validating enzymatic data, several ancillary results were found. By exam-
ining sibling residues, enzymatic complexes or any possible substrate specificity for an enzyme
were identified. Although this analysis did not provide definitive identification of these proper-
ties, it served to identify potentially interesting reactions to be examined further through wet lab
procedures.
A comprehensive list of glycosyltransferases was obtained through the verification process,
and several new reactions without enzymatic data were identified. Linkages that resulted from
errors in data entry were also identified.
The verification process yielded a matrix of verified glycosyltransferases (Section A.1). This
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matrix contains several entries that are new to existing reaction matrices, and are indicative of
deficiencies in the summaries of data already provided [11]. The 11 reactions not associated with
enzymatic information must be investigated through further experimental methods.
As enzymes were verified, linkages and their associated reactions were deemed to be artefacts
if the reference evidence did not support the presence of these linkages. The volume of eliminated
linkages highlights the large number of errors found in existing databases.
To realise the verification and validation of data, software was developed in the Ruby language
as a web application. In addition, a software toolkit was developed to allow for varied analyses to
be performed on sequence data originating from many sources.
Pathway validation — the process of checking biosynthetic pathway data against the database
— resulted in the confirmation that the pathways from KEGG are representative of the structures
in the database. In addition, extensions to the pathways were identified, comprising Type I/II
chain extensions, terminal epitope elaborations and fucosylation. Patterns in chain formationwere
observed, which limits the number of structures that can be formed. Information about chain
length, degree of fucosylation and degree of branching was not established in this analysis. From
the information gathered, it is possible to determine whether a structure has a core structural
component that exists in known pathways, and which extensions have been combined to result in
the end structure.
The results shown here indicate—for human structures, at least — that there is an upper limit
on the diversity of glycans, and that their synthesis is regulated strongly by known biosynthetic
pathways. This limitation on diversity permits algorithms to be developed that can be used to
verify structures deposited into databases. This will facilitate both syntax and context based vali-
dation of sequences, significantly reducing the difficulty involved in maintaining the database.
6.1 Structural diversity
A significant conclusion from this study is that there is an upper limit to the diversity of human
glycans, significantly lower than some previous liberal estimates of the size of the human gly-
come. Structures can be grouped into sets of elaborations on core structures with Gal→ GlcNAc
linkage repeating extension units, and various structural epitopes or residues at terminal posi-
tions. A number of new disaccharides have been identified, suggesting the presence of further
glycosyltransferases which could synthesise these linkages. No position along the pathway for
these enzymes has been proposed. Calculations to estimate the size of the human glycome, based
on the listed model of glycosylation, suggest an estimated 340,000 glycan structures. Numerous
flaws in the model were identified, and further data mining is needed to refine the model for a
more accurate estimate of the size of the glycome.
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6.2 Structural validation tool
Using a codification of the structural features and pathway information elucidated in this study,
it is possible to write a software tool which will permit the verification of structures to gauge their
contextual relevance to human structures. As an exemplar of such an endeavour, the validation
algorithm was implemented as a web-application for the validation of structures entered using
a specialised input tool. This has limited general applicability, since glycan databases typically
contain structures from a wide variety of species. For a verification tool to be generally valid,
a similar analysis must be performed for each system to ensure that the pathway information is
valid.
6.2.1 EUROCarbDB network layer
The validation methodology was developed for the EUROCarbDB project. The validation allows
for open curation of the database to be more easily managed, and allows its quality to be main-
tained despite the absence of centralised management. The decentralisation of the database has
also been facilitated in this thesis by the establishment of a network layer within the project. The
two major results from this work are that queries on the database can be transparently distributed
to other databases on the network, and that facilities for the transfer of large data sets are now
built into the EUROCarbDB application.
6.3 Future directions
This analysis rests on a fundamental and logical leap of faith: That the sequences studied and
deposited into databases are in some way representative of the entire spectrum of the human gly-
come. Verifying this is impossible without performing a concerted sequencing effort for the entire
human glycome. Any further improvement on this work will not come through pure bioinformat-
ics — but rather will be realised through an effort to provide complete sets of glycomes for further
study. This requires more efficient high-throughput analytical methods, which in turn requires
better bioinformatics to analyse the resulting data.
There exist tangential applications for extension of the work surrounding the study of glycan
diversity. Areas such as the automatic sequencing and analysis of glycan profiling and mass spec-
trometric data could benefit from such insights. An automatic algorithm for detection of glycan
structures from mass spectrometric data is feasible, combining structural information from path-
way data with spectral data to limit the combinatorial explosion inherent in de-novo sequencing.
It should also be possible to design tests for spectral data to find peaks that do not agree with
pathway data, and are thus indicative of fundamental differences in the glycosylation machinery
— allowing one to skip over the core logical fallacy inherent in this analysis, and discover new
87
structural features.
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Appendix A
≈
Additional data
A.1 Human glycosyltransferases collected
Reaction Genes
Gal(β1→4)⇒ GlcNAc B4GALT1, B4GALT2, B4GALT3, B4GALT4,
B4GALT5, B4GALT6
Gal(α1→4)⇒ Gal A4GALT
Gal(β1→4)⇒ Glc B4GALT6
Gal(β1→3)⇒ GalNAc C1GALT1, C1GALT1C1, B3GALT4, B3GALT5
Gal(β1→3)⇒ Gal B3GALT6
Gal(β1→3)⇒ GlcNAc B3GALT1, B3GALT2
Gal(α1→3)⇒ Gal ABO, GGTA1
Gal(β1→0)⇒ Cer UGT8
Gal(β1→4)⇒ Xyl B4GALT7
GalNAc(β1→4)⇒ GlcA GALNACT-2, CHSY1
GalNAc(α1→3)⇒ GalNAc GBGT1
GalNAc(α1→0)⇒ Ser GALNT1, GALNT2, GALNT3, GALNT4, GALNT5,
GALNT6, GALNT7, GALNT8, GALNT9, GALNT10,
GALNT11, GALNT12, GALNT13, GALNT14, GAL-
NTL4
GalNAc(β1→4)⇒ Gal B4GALNT1, B4GALNT2
GalNAc(α1→0)⇒ Thr GALNT1, GALNT2, GALNT3, GALNT4, GALNT5,
GALNT6, GALNT7, GALNT8, GALNT9, GALNT10,
GALNT11, GALNT12, GALNT13, GALNT14, GAL-
NTL4
GalNAc(α1→3)⇒ Gal ABO
GalNAc(β1→3)⇒ Gal B3GALNT1
GalNAc(β1→3)⇒ GlcNAc B3GALNT2
GalNAc(β1→4)⇒ GlcNAc B4GALNT3, B4GALNT4
Glc(β1→0)⇒ Cer UGCG, UGCGL1
Continued on next page
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Table A.1 – continued from previous page
Reaction Genes
Glc(α1→3)⇒Man ALG6
Glc(α1→3)⇒ Glc ALG8
Glc(α1→2)⇒ Glc ALG10
Glc(β1→3)⇒ Fuc B3GALTL
GlcNAc(β1→3)⇒ GalNAc B3GNT6
GlcNAc(β1→4)⇒ GlcNAc ALG13, ALG14
GlcNAc(β1→0)⇒ Ser OGT
GlcNAc(β1→4)⇒ GlcA HAS1, HAS2, HAS3
GlcNAc(β1→0)⇒ Thr OGT
GlcNAc(β1→3)⇒ Gal B3GNT1, B3GNT2, B3GNT3, B3GNT4, B3GNT5,
B3GNT6, B3GNTL1
GlcNAc(β1→2)⇒Man POMGNT1, MGAT1, MGAT2
GlcNAc(β1→3)⇒ Fuc LFNG, RFNG
GlcNAc(β1→6)⇒ GalNAc GCNT1, GCNT3, GCNT4
GlcNAc(β1→6)⇒Man MGAT5, MGAT9, MGAT5B
GlcNAc(α1→4)⇒ Gal A4GNT
GlcNAc(β1→6)⇒ Gal IGNT2, IGNT3, GCNT2, GCNT3
GlcNAc(α1→4)⇒ GlcA EXTL1, EXTL2, EXTL3
GlcNAc(β1→4)⇒Man MGAT3, MGAT4A, MGAT4B, MGAT9
GlcA(β1→4)⇒ GlcNAc EXT1, EXT2
GlcA(β1→3)⇒ GlcNAc HAS1, HAS2, HAS3
GlcA(β1→3)⇒ GalNAc CHSY1
GlcA(β1→3)⇒ Gal B3GAT3, B3GAT1, B3GAT2
Man(α1→0)⇒ Ser POMT1, POMT2
Man(α1→3)⇒Man ALG2, ALG3
Man(α1→0)⇒ Thr POMT1, POMT2
Man(β1→4)⇒ GlcNAc ALG1
Man(α1→6)⇒Man ALG2, ALG12
Man(α1→4)⇒ GlcN PIGM
Man(α1→2)⇒Man non-HomoSapiens, ALG9, PIGB
NeuAc(α2→6)⇒ GalNAc ST6GAL1, ST6GALNAC1, ST6GALNAC2,
ST6GALNAC3, ST6GALNAC4, ST6GALNAC5,
ST6GALNAC6
NeuAc(α2→8)⇒ NeuAc ST8SIA1, ST8SIA2, ST8SIA3, ST8SIA4, ST8SIA5,
ST8SIA6
Continued on next page
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Table A.1 – continued from previous page
Reaction Genes
NeuAc(α2→6)⇒ Gal ST6GAL1, ST6GAL2, ST6GALNAC1,
ST6GALNAC2, ST6GALNAC3, ST6GALNAC4
NeuAc(α2→3)⇒ Gal ST3GAL1, ST3GAL2, ST3GAL3, ST3GAL4,
ST3GAL5, ST3GAL6
Xyl(β1→2)⇒Man non-HomoSapiens
Xyl(β1→0)⇒ Ser XYLT1, XYLT2
Fuc(α1→3)⇒ GlcNAc FUT3, FUT4, FUT5, FUT6, FUT7, FUT11, FUT9
Fuc(α1→4)⇒ GlcNAc FUT3, FUT5, FUT6
Fuc(α1→0)⇒ Ser POFUT1, POFUT2
Fuc(α1→2)⇒ Gal FUT1, FUT2
Fuc(α1→6)⇒ GlcNAc FUT8
Fuc(α1→0)⇒ Thr POFUT1, POFUT2
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A.2 Structures known to be artefacts
Glycosciences ID
612 3994 11252 13424 16541 25759
624 3995 11258 14899 16542 26057
1172 3999 11259 15025 16598
1241 4151 11260 15235 16685
1737 4521 11261 15891 16732
1774 4522 11352 16048 16735
1775 4523 11732 16085 16736
2652 4524 11733 16163 16737
2740 4951 11734 16164 16850
2747 4957 11735 16167 18548
2854 5152 11736 16171 19743
2921 5334 11785 16172 20279
2922 5376 11786 16270 20282
2924 6637 12157 16271 23725
3152 6655 12209 16320 23726
3697 6667 12210 16371 23737
3823 7477 12211 16414 23738
3825 7753 12212 16423 24339
3826 7763 12213 16432 24340
3827 8104 12445 16433 24341
3846 8393 12833 16458 24403
3847 8668 12867 16482 25613
3848 9689 13305 16485 25678
3849 10909 13306 16486 25679
3961 10957 13322 16502 25699
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A.3 Human pathway diagrams
Figure A.1: Structure comprising structures along the O-linked pathway.
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Figure A.3: Structure comprising structures along the GSL pathway.
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